Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.
Advertise on Glaucoma, Vision & Longevity: Supplements & Science
Advertise on Glaucoma, Vision & Longevity: Supplements & Science to promote your brand to thousands of podcast listeners
How Many Days Should You Measure Eye Pressure at Home? A New Study Finds 7–10 Days May Be the Sweet Spot
2026/11/14
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/how-many-days-should-you-measure-eye-pressure-at-home-a-new-study-finds-7-10-days-may-be-the-sweet-spot
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
How Many Days Should You Measure Eye Pressure at Home? A New Study Finds 7–10 Days May Be the Sweet Spot
One eye-pressure reading at a clinic is a snapshot. It may miss changes that happen before work, in the evening, or overnight. A study published in Ophthalmology on November 2, 2026, tested how many days of home measurements are needed to estimate a person’s pressure pattern more reliably. Its practical answer is about seven to ten consecutive days, with readings taken at different times of day—not just once daily. Jensen and colleagues’ study ()
That is a useful starting point, not a guarantee that every pressure peak will be found. The study estimated how well additional days improved pressure summaries compared with all the readings available for each monitoring period. It did not prove that ten days of home testing prevents vision loss, or that an observed peak is automatically harmful.
The short answer
For many patients: seven days with at least three readings spread across the day gave a more stable estimate of average pressure, daily maximum, daily range, and daily variation.
For primary open-angle glaucoma: the study’s models often favored nine to ten days.
For a high-risk patient: a reasonable practical plan to discuss with a glaucoma specialist is ten consecutive days, with four to six readings per day at different times. Three time periods per day is the study’s minimum useful pattern, not a proven ideal for every person.
A peak is not a diagnosis. Repeated pressure readings above a person’s own target, interpreted alongside optic nerve and visual-field findings, matter more than one isolated high number.
These are population-level findings from a retrospective study, not a new requirement for every person with glaucoma. The American Academy of Ophthalmology describes home tonometry as promising, but its current guidance does not set a universal home-measurement schedule. ()
What the November 2026 study actually measured
The study included patients using the iCare HOME or iCare HOME2 rebound tonometer. The authors began with 397 patients from the Moran Eye Center and Wilmer Eye Institute and 1,579 patients in the MyEyes database. Those are the total database counts, not the number in the main analysis: after applying the study’s requirements for readings at different times of day, the primary analysis included 326 Moran/Wilmer patients and 1,182 MyEyes patients. It covered 729 monitoring periods and 31,416 readings in the first dataset, and 2,572 periods and 131,522 readings in the second. The full study ()
The researchers compared estimates based on fewer randomly selected monitoring days with each eye’s full-period record—all usable readings in that monitoring period. They modeled how the error decreased as days were added, and called the point at which 95% of the maximum modeled error reduction had occurred the optimal duration. That phrase does not mean a patient has a 95% chance of recording every true pressure peak. The “full-period record” is also not a perfect ground truth: pressure peaks can still be missed between readings or during sleep. ()
Participants were asked to take at least six readings per day for seven or more days, with particular emphasis on an early-morning reading. For the primary analysis, a day had to include readings in at least three periods: morning, midday, and evening. In practice, the median number of daily readings was 5.6 in Moran/Wilmer and 6.3 in MyEyes. So the headline result comes from people generally taking more than three readings on many days, even though the analysis required coverage of at least three daily periods. ()
Average pressure, peaks, range, and variation
The table shows the average daily pressure summaries in eyes that met the three-period requirement. The days column gives the model’s estimate for achieving 95% of the maximum modeled reduction in error.
For the full table, please open this article on visualfieldtest.com.
These are study-cohort averages, not an expected reading for every patient. The authors also found lower average daily range and variation when they included all valid readings without requiring all three time periods. That is a reminder that the primary sample was selected for having more complete, spread-out measurements. ()
How much did estimates improve with more days?
The next table reports the mean absolute error—the average difference between an estimate based on a limited number of days and the full-period estimate. The one-day value is based on a day with readings spread across the required time periods; it is not the error from taking one reading total.
For the full table, please open this article on visualfieldtest.com.
All error values are in mm Hg. The study also analyzed pressure summaries calculated across the entire monitoring period rather than daily summaries. Those estimates generally reached the same modeled threshold in about four to six days, depending on the metric and dataset. ()
The confidence intervals above describe the estimated errors at particular durations. The paper does not provide equivalent confidence intervals around the exact day-count estimates. The day counts are model-based point estimates, and the authors caution that longer-duration results become less stable as fewer people contribute data.
Morning peaks and pressure variation between days
In the MyEyes dataset, the recorded peak occurred in these time windows:
For the full table, please open this article on visualfieldtest.com.
In a separate analysis using typical office hours of 8 a.m. to 4:59 p.m., only 25.9% of recorded peak events fell within that window; 74.1% occurred outside it. These are peak events in the recorded dataset, not the proportion of all glaucoma patients guaranteed to have a harmful peak. The readings were intermittent, so the actual highest pressure could have occurred between measurements. ()
The study did not report a separate measure of between-day variation as a standalone outcome. Instead, it tested how reliably daily mean, maximum, range, and standard deviation could be estimated as more days were included. It also did not show that early morning was the peak period for every patient. In these data, recorded peaks occurred across the full day and night.
Does home testing find pressure missed at the clinic?
It can—in selected patients referred for home monitoring—but the chance depends on who is tested and how “a problem” is defined.
A 2021 study of 107 glaucoma eyes compared a week of home readings with up to five prior clinic readings. Average pressure was slightly lower at home than in the clinic, but home testing found higher maximums and wider fluctuations. The mean of each day’s maximum was more useful for avoiding over-reliance on one possibly spurious high reading than the single highest reading in the whole week. McGlumphy and colleagues’ study ()
In that selected group:
The mean of daily home maximums exceeded the mean clinic pressure by at least 3 mm Hg in 36.4% of eyes and by at least 5 mm Hg in 21.5%.
It exceeded the highest recorded clinic pressure in 43.9% of eyes.
Among 74 eyes with a documented pressure target, the mean of daily home maximums exceeded the target in 47 eyes. In 18 of those 74 eyes (24.3%), no prior clinic reading had exceeded the target.
When counting any home reading above target rather than the mean of daily maximums, 21 of the 55 eyes with an above-target home reading had no clinic reading above target. ()
A newer, highly selected study looked at 82 eyes with generally acceptable clinic readings but other high-risk features. Its average baseline clinic pressure was 13.08 mm Hg. The investigators defined a home “spike” as a reading more than 5 mm Hg or 30% above the baseline clinic pressure. By that definition, 72% of eyes had a spike; among those, about half had a change in treatment or a procedure recorded after home testing. A spike alone did not dictate a treatment change. This is evidence about a high-risk referral group—not a general estimate for every person with glaucoma. Kim and colleagues’ 2026 study ()
What if the clinic reading is 10, 12, or 15 mm Hg?
The available studies do not publish reliable probabilities for how often an eye with a specific clinic reading of 10, 12, or 15 mm Hg will have a substantially higher home pressure. They do not provide a useful table of hidden-peak rates at each of those three starting values. It would be misleading to invent one.
The best available benchmarks come from the selected groups above: roughly one in four eyes in the 2021 study had a mean-of-daily-maximum home pressure above the documented target when clinic readings had not crossed that target; in the more highly selected 2026 group, about three in four met a broad “spike” definition. These figures have different populations and definitions, so they should not be combined into one universal probability. The 2021 study also described individual cases with clinic pressures in the low teens or below and repeated early-morning home elevations; those cases show what is possible, not how common it is. ()
A low clinic pressure does not, by itself, establish that a patient’s pressure remains below their
Support the show
Scientists Found a New Way to Open the Eye's Natural Drainage System — Could It Lead to Better Glaucoma Drops?
2026/11/11
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/scientists-found-a-new-way-to-open-the-eye-s-natural-drainage-system-could-it-lead-to-better-glaucoma-drops
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Scientists Found a New Way to Open the Eye’s Natural Drainage System — Could It Lead to Better Glaucoma Drops?
A study published on November 5, 2026 points to a possible new way to improve the eye’s natural fluid drainage: change the mechanical behavior of the cells lining Schlemm’s canal, a circular drainage channel near the front of the eye. In laboratory experiments, the cancer drug paclitaxel altered these cells’ stiffness and pore formation. In isolated mouse eyes, it increased measured fluid outflow facility by 44.3%.
That is an intriguing result—but it is not evidence that paclitaxel is a glaucoma treatment, and the experiment did not show a 44.3% fall in eye pressure. The study used cultured human cells and short-term experiments in enucleated mouse eyes, not people receiving eye drops. It also leaves open questions about which drainage tissues produced the effect, whether the proposed signaling pathway explains it, and whether a safer drug can reproduce it.
The most careful answer to the central question is: possibly. Restoring a healthier mechanical response in the drainage pathway could become a useful treatment strategy, but the drug, delivery method, and clinical benefit are not yet established. The November 2026 study and its PubMed record ()
How the eye’s natural drainage system works
The eye continually makes a clear fluid called aqueous humor. It flows from behind the iris, through the pupil, and into the front chamber of the eye. Most then leaves through the conventional outflow pathway:
It passes through the trabecular meshwork, a porous tissue at the eye’s drainage angle.
It crosses a thin layer of cells lining the inner wall of Schlemm’s canal.
It enters the canal, then passes into collector channels and veins before joining the circulation.
A smaller, separate amount leaves through the uveoscleral pathway, through tissues near the ciliary muscle. The conventional pathway is pressure-dependent: generally, fluid leaves faster when the pressure inside the eye is higher than the pressure in the veins receiving it. The conventional route and aqueous humor circulation are summarized by the National Center for Biotechnology Information ()
How fluid crosses Schlemm’s canal’s inner wall
The inner wall is not simply a passive sieve. Its endothelial cells respond to pressure and stretch. As aqueous humor pushes against them, the cells can bulge toward the canal, forming temporary, fluid-filled outpouchings called giant vacuoles. A pore can form through a stretched cell, allowing fluid to pass into the canal; this is a transcellular pore. Fluid can also pass between neighboring cells through paracellular, or border, pores. A review of Schlemm’s canal cell physiology and a recent review of canal development and function describe both routes. ()
Pore formation is relevant to glaucoma, but it is not a settled, simple measurement of drainage. Studies of human donor eyes have reported fewer pores in glaucoma, while also showing that postmortem time and tissue fixation affect the apparent pore count. Some researchers have cautioned that at least some observed pores could be artifacts of tissue preparation. A human-eye study reported lower pore density in glaucoma; another study documented the influence of fixation conditions. ()
What the November 2026 study tested
The researchers combined three types of experiment:
Cultured primary human Schlemm’s canal cells from donors without glaucoma and donors with glaucoma.
Cell mechanobiology tests, including measurements of cell stiffness, contractility-related markers, and mechanically induced pore formation.
Whole-eye perfusion experiments in isolated mouse eyes, measuring how readily fluid flowed through the conventional outflow pathway.
The study used four normal and four glaucoma-derived human cell strains. Each experiment used a smaller subset, usually three strains per group or condition. The glaucoma-derived strains came from donors aged 71 to 78 years; the normal strains ranged from infancy to 68 years. That age difference is important: donor age may influence cell biology, and the groups were not age-matched. The study’s authors note the limitation. The final published article’s donor table and methods list the strains and experimental details. ()
Drug concentrations and experimental conditions
For the full table, please open this article on visualfieldtest.com.
The cultured-cell concentration was 10 micromolar; the nominal concentration in the mouse-eye perfusate was 100 micromolar. Only one principal paclitaxel concentration was tested in each setting, so the study does not establish the lowest effective dose, a dose-response curve, or a safe long-term exposure. The paper’s perfusion methods explain the 100-micromolar perfusate and estimated dilution. ()
What changed in the cultured cells
The reported results included:
Lower microtubule-stability markers in glaucoma-derived Schlemm’s canal cells. The researchers measured acetylated alpha-tubulin, a marker associated with stable microtubules.
Lower cell stiffness after paclitaxel. In normal cells, paclitaxel reduced measured stiffness by 36.4%; nocodazole increased it by 44.0%.
Lower phosphorylated myosin light chain after paclitaxel. After 30 minutes, this contractility-related marker fell by 35.1% (p Glaucoma-related tissue stiffening → reduced microtubule stability → increased GEF-H1/RhoA/ROCK signaling → greater cellular contraction → fewer drainage pores → increased outflow resistance → elevated eye pressure
The evidence supports some links directly, some only partly, and others mainly as a plausible model.
For the full table, please open this article on visualfieldtest.com.
The human-eye stiffness results are consistent with earlier work on the Schlemm’s canal inner wall, while the hydrogel experiment directly tested cell response to two substrate stiffnesses. A human donor-eye study of inner-wall stiffness and the 2026 study’s stiffness experiment support these distinctions. ()
An important complication: paclitaxel may not simply “hold” GEF-H1 on microtubules
The 2026 glaucoma study’s explanation treats microtubule stabilization as a way to suppress GEF-H1-linked contraction. But a separate study published in September 2026 found that taxanes—including paclitaxel—can rapidly change the microtubule lattice and release GEF-H1, activating RhoA signaling in other cell systems. That work used cell biology and purified-protein experiments; it did not test human Schlemm’s canal cells. The Nature Cell Biology study reports this taxane-specific effect. ()
This does not automatically invalidate the glaucoma result. Different cell types, exposure conditions, and microtubule structures may produce different responses. But it does mean that “more stable microtubules” cannot yet be treated as a universal synonym for “less GEF-H1 activity.” The eye study did not directly show that paclitaxel kept GEF-H1 bound to microtubules or lowered RhoA activity in Schlemm’s canal cells. That question needs to be tested directly before the proposed pathway can be considered settled.
Acetylation is a marker, not a complete explanation
The study used acetylated alpha-tubulin as a marker associated with stable microtubules. The enzyme al
Support the show
Hot Tubs and Glaucoma: The Overlooked Effects of Warm-Water Immersion
2026/11/10
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/hot-tubs-and-glaucoma-the-overlooked-effects-of-warm-water-immersion
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Hot Tubs and Glaucoma: The Overlooked Effects of Warm-Water Immersion
A hot tub can affect more than comfort. Warm water and immersion can change blood pressure, heart rate, and blood flow—and these changes may matter to the eye as well as to balance and safety. Yet the limited research does not show that ordinary hot-tub use raises eye pressure or worsens glaucoma.
The practical takeaway: For most people whose glaucoma is stable and who have no recent eye-surgery restrictions, a brief, comfortable hot-tub soak is generally reasonable. Glaucoma alone is not a reason to avoid hot tubs. The bigger known concern is dizziness or fainting when getting out. Extra caution makes sense for people with low blood pressure, a history of fainting, concerns about optic-nerve blood flow, or recent glaucoma surgery.
How hot water could affect the eye
Eye pressure and blood supply are different concerns
Glaucoma damages the optic nerve, which carries visual information from the eye to the brain. Intraocular pressure is the pressure of fluid inside the eye. Lowering it is a main way to reduce the risk of further damage.
The optic nerve also needs a steady blood supply. Ocular perfusion pressure is an estimate based on blood pressure and eye pressure; it is not a direct measurement of blood flowing through the optic nerve. The American Academy of Ophthalmology notes that low ocular perfusion pressure may contribute to optic-nerve damage, but research cannot always separate the effects of blood pressure from those of eye pressure. Long-term studies have linked low blood-pressure patterns with progression in some people with glaucoma, but they do not show that a normal, brief soak damages the optic nerve. American Academy of Ophthalmology’s glaucoma guidance. ()
Heat, immersion, and posture can act together
Heat widens blood vessels near the skin and can lower blood pressure. Immersion also changes how blood is distributed in the body. Heart rate may rise as the body responds to heat. The combined effect varies from person to person and depends on water temperature, soak length, posture, and health.
Posture matters because eye pressure often rises when a person moves from sitting upright to lying flat or with the head lowered. A recent review estimated an average rise of about 2.9 millimeters of mercury when people in the glaucoma spectrum moved from sitting to lying flat. That finding is about body position, not hot tubs. It does not mean that sitting upright in a tub causes the same change. Systematic review of posture-related eye-pressure changes and study of different postures in people with open-angle glaucoma. ()
What the research says
Direct evidence from hot tubs is limited
One small study is especially relevant: 34 young, healthy adults sat upright with water up to their shoulders in a 39°C (102°F) hot pool for 20 minutes. Researchers measured eye pressure and blood pressure before the soak, just after it, and five minutes later. Eye pressure and blood pressure fell after immersion, while heart rate increased. The researchers also calculated a decrease in ocular perfusion pressure.
This result does not show that a hot tub harms people with glaucoma—or that it treats glaucoma. The participants did not have glaucoma, the study examined only one session, and the measurements were not taken continuously during the soak. The calculated perfusion pressure was an estimate, not a direct measurement of blood reaching the optic nerve. Study of blood and eye pressure after hot-water immersion. ()
Other warm-water and heat studies are not hot-tub studies
Some research helps explain why eye responses may vary, but it should not be treated as proof about hot tubs:
In one study, 23 healthy volunteers soaked their feet in 40°C water for one minute. Immediately afterward, their estimated ocular perfusion pressure and a measure of blood-flow speed in the choroid—a blood-vessel layer at the back of the eye—fell briefly. The blood-flow measure was back near its starting level after ten minutes. This was a foot soak, not whole-body immersion, and it did not measure blood flow at the optic nerve. Study of warm foot immersion and choroidal blood flow. ()
In a different experiment, 12 healthy young men wore a heated suit while resting. This was not a bath or hot tub. After prolonged heat exposure, blood-flow measures in retinal and choroidal vessels decreased, even though blood pressure did not change. The long, controlled exposure is quite different from a typical soak. Study of passive heat stress and ocular blood flow. ()
A temperature challenge involving people with primary open-angle glaucoma used warm water on one hand, followed by cold water. It was not whole-body bathing. The study therefore cannot establish whether hot tubs are helpful or harmful for people with glaucoma. Study of temperature provocation in glaucoma. ()
Together, these studies suggest that warmth and immersion can briefly affect blood pressure and some blood-flow measures. They do not establish that hot-tub use causes glaucoma progression.
What posture may mean in a tub
Most hot-tub use is seated, with the head above water. That is different from lying flat, leaning far back, or keeping the head below the level of the chest for a long time. Posture studies—not hot-tub studies—show that lying flat, lying on one side, or lowering the head can raise eye pressure compared with sitting upright.
If you have been told that your eye pressure rises substantially with posture, it is reasonable to ask your eye doctor whether your usual reclining position matters. There is no evidence that people with stable glaucoma need to avoid an ordinary upright soak. ()
Dizziness, blood pressure, and dehydration
Getting out may be riskier than sitting in
Heat can lower blood pressure while widening blood vessels. When a person stands, blood can pool in the legs; the body may not adjust quickly enough to keep blood flowing to the brain. This can cause orthostatic hypotension—a blood-pressure drop on standing—with lightheadedness, blurred vision, weakness, or fainting.
In one small study, a ten-minute soak in 40°C water caused substantial blood-pressure drops in both people with treated high blood pressure and people with normal blood pressure, although none of the participants reported symptoms. Another study found that a short warm bath temporarily reduced the body’s heart-rate response to standing. These studies are not proof that everyone will feel dizzy, but they show why it is sensible to get out slowly. Hot-tub blood-pressure study and warm-water immersion study of the body’s response to standing. ()
Long, hot soaks can add fluid loss
Being surrounded by water does not prevent sweating. In a study involving 60 minutes of hot-water immersion, participants lost an average of about one liter of fluid, but they also drank a similar amount. That was a prolonged research session, not a typical short soak; it does not mean that every hot-tub visit causes substantial dehydration. Still, starting well hydrated and avoiding a long soak when ill or already dehydrated are sensible precautions. If you have a medical fluid restriction, follow your clinician’s advice rather than increasing fluids on your own. Study of fluid loss during prolonged hot-water immersion. ()
When the risk assessment may change
Talk with your eye doctor or another health professional before using a hot tub—or take extra care—if you have:
Advanced or actively worsening glaucoma, especially if your clinician has raised concerns about low blood pressure or blood flow to the optic nerve.
Low blood pressure, dizziness on standing, or a history of fainting.
A condition that affects the body’s automatic blood-pressure control, such as some nerve disorders.
A recent illness, vomiting, diarrhea, or dehydration.
Medicines that lower blood pressure or increase fluid loss. Do not stop or change prescribed medicines on your own.
Recent glaucoma surgery. Water-exposure instructions vary by procedure and surgeon. Follow your surgical team’s advice before using a hot tub; after some glaucoma operations, water exposure can pose an infection risk. American Academy of Ophthalmology guidance on returning to activity after eye surgery. ()
Practical precautions for people with glaucoma
Keep the water at or below 104°F (40°C), the maximum temperature recommended by the Centers for Disease Control and Prevention. Avoid prolonged soaks, particularly at the hottest setting. Centers for Disease Control and Prevention hot-tub safety guidance. ()
Prefer a comfortable seated position over lying flat or keeping your head lowered for a long time.
Get out slowly. If you are prone to dizziness, use a handhold and have someone nearby.
Avoid alcohol before or during a soak. Do not use the tub if you already feel faint, unwell, or dehydrated.
Leave the water if you feel lightheaded, nauseated, weak, or unusually unsteady. Do not try to “push through” symptoms.
Conclusion
For a person with stable glaucoma and no recent surgical restrictions, brief, ordinary hot-tub use is generally reasonable. Current evidence does not show that it raises eye pressure or worsens glaucoma. However, research in people with glaucoma is limited, and warm-water immersion can tempora
Support the show
Scientists Found a New Way to Make Injured Optic Nerve Cells Regrow — Could It Help Restore Vision in Glaucoma?
2026/11/07
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/scientists-found-a-new-way-to-make-injured-optic-nerve-cells-regrow-could-it-help-restore-vision-in-glaucoma
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Scientists Found a New Way to Make Injured Optic Nerve Cells Regrow — Could It Help Restore Vision in Glaucoma?
Short answer: The study offers a stronger explanation for how melanopsin can encourage injured retinal ganglion cells to grow axons: light-sensitive signaling through TRPC channels and cyclic adenosine monophosphate appears to work together. The results make the pathway more interesting as a research target, but they do not show that light exposure regrows a human optic nerve, that the new fibers reconnect correctly in the brain, or that vision returns in glaucoma.
A reporting caveat matters here. The Proceedings of the National Academy of Sciences paper appeared online on October 27, 2026, and in the November 3, 2026 issue. Its accessible abstract describes the main findings but does not include the detailed axon counts, growth distances, sample sizes, exact statistical tests, or treatment schedule. I cannot verify those numbers from the available full-text record, so I will not invent them. Where possible, I distinguish the new paper from a related 2016 melanopsin study that does report additional experimental details. ()
What the November 2026 study tested
The study used mice with an optic-nerve-crush injury, a laboratory model in which retinal ganglion cell axons are deliberately crushed. The researchers introduced OPN4, the gene for the light-sensitive protein melanopsin, into retinal ganglion cells. They then examined light responses in the cells and assessed axon growth after injury. The paper identifies the successfully infected cells as OPN4-expressing retinal ganglion cells. ()
The authors compared two broad groups of retinal ganglion cells:
Alpha retinal ganglion cells: relatively large cells that include several distinct subtypes.
Non-alpha retinal ganglion cells: the diverse remaining population—not one uniform cell type.
They report that OPN4-expressing alpha cells produced both a fast, TRPC-dependent light response and a slower, cyclic adenosine monophosphate-dependent response. OPN4-expressing non-alpha cells showed mostly the fast response. The researchers then disrupted the relevant pathways genetically and tested whether supplying cell-permeant cyclic adenosine monophosphate could restore or increase regeneration. ()
This is more than a simple comparison of “gene therapy versus no gene therapy.” Removing the signaling components and then rescuing one of the effects with cyclic adenosine monophosphate provides evidence that the pathways matter to the reported growth response. It does not, by itself, establish that the resulting axons reconnect to the right brain circuits or restore vision.
What the reported numbers do—and do not—show
The paper’s accessible abstract reports the direction of the main effects, but not the underlying numerical data. In particular, it does not provide exact axon counts, farthest-growth distances, survival percentages, sample sizes, or p-values. Those numbers should be checked against the article’s figures and supporting information before being quoted.
For the full table, please open this article on visualfieldtest.com.
“Not stated in the abstract” is not the same as “the result was zero.” It means I cannot responsibly supply a numerical answer without verifying the full paper. The central mechanistic conclusion—that disrupting either pathway reduced the reported regeneration, while cyclic adenosine monophosphate could compensate for part of the deficit—is supported by the published abstract. ()
What the earlier melanopsin experiment established
A related 2016 study provides useful context, but its numbers should not be mistaken for results from the November 2026 paper. In that earlier mouse experiment, researchers delivered melanopsin using an adeno-associated virus, waited four weeks, crushed the optic nerve, and assessed growth two weeks after injury. Some axons extended more than 2 millimeters beyond the injury site. The study’s figure legend reports six mice per group for its main regeneration comparison. ()
The earlier study also found that retinal ganglion cell survival was similar with and without melanopsin treatment. Among the cells identified as regenerating, 95% were labeled as alpha retinal ganglion cells in one tracing experiment, and 92% in an ex vivo experiment. These findings point to a major limitation: melanopsin expression did not make all retinal ganglion cell types equally regenerative. ()
That 2016 study did not show that melanopsin-treated axons reached the brain’s superior colliculus. Its researchers checked that the crush had blocked tracing to the superior colliculus, and reported no labeled axons there. The reported growth beyond 2 millimeters was therefore evidence of axon extension, not restored visual circuitry. ()
How melanopsin could promote growth
Melanopsin is a light sensor in some retinal ganglion cells
Melanopsin, encoded by OPN4, is normally found in a small subset of retinal ganglion cells called intrinsically photosensitive retinal ganglion cells. Unlike most retinal ganglion cells, these cells can respond directly to light, even without receiving the usual light signals from rod and cone photoreceptors. They contribute especially to non-image-forming functions such as pupil responses and daily body rhythms. ()
The new study’s approach was to add melanopsin to other retinal ganglion cells. In effect, it gave those cells a new light-sensitive signaling input. The abstract reports that the infected cells developed both rhabdomeric-like and ciliary-like signaling responses—the two pathway motifs the authors associate with melanopsin responses in retinal ganglion cells. ()
The fast branch: TRPC channels and mTOR
In the fast pathway, light activates melanopsin and sets off signaling involving a G protein and phospholipase C. That signaling can open transient receptor potential canonical channels, especially TRPC6 and TRPC7. The resulting flow of charged particles into the cell can depolarize it and change intracellular calcium. ()
The 2026 paper’s significance statement links this TRPC branch to mammalian target of rapamycin signaling, a cellular growth-control pathway. In the new study, removing TRPC6 and TRPC7 largely reduced the melanopsin-associated regeneration in alpha retinal ganglion cells. That is evidence that these channels contribute to the growth response; it does not mean that simply opening TRPC channels would be a safe or sufficient treatment. Calcium signaling can support cell activity, but excessive or poorly controlled calcium can also harm stressed neurons. ()
The slower branch: adenylyl cyclases and cyclic adenosine monophosphate
The second response involves adenylyl cyclases 2, 4, and 7, which can make cyclic adenosine monophosphate—often written as cyclic adenosine monophosphate or cAMP, not to be confused with other cyclic nucleotides. The paper identifies a slower, cyclic-adenosine-monophosphate-linked light response in OPN4-expressing alpha cells and describes a role for protein kinase A in its growth mechanism. ()
Removing the three adenylyl cyclases largely attenuated regeneration in the OPN4-expressing alpha cells. Supplying cell-permeant cyclic adenosine monophosphate reportedly rescued that knockout effect. It also increased regeneration in some OPN4-expressing non-alpha cells, which suggests that a weak cyclic-adenosine-monophosphate signal may be one barrier to growth in at least some cell types. It does not establish that cyclic adenosine monophosphate alone can replace every effect of melanopsin. ()
Why cell type matters—and why “resistant” does not mean “regenerative”
Retinal ganglion cells are a varied population. Different types can differ in their vulnerability to injury, their survival, their growth capacity, and the brain targets they normally connect to. In mouse optic-nerve-injury experiments, alpha retinal ganglion cells have shown relatively strong survival and growth responses to some treatments, in part associated with stronger growth signaling and expression of factors such as osteopontin and insulin-like growth factor 1. But this advantage does not extend uniformly to every alpha subtype or every injury. ()
Intrinsically photosensitive retinal ganglion cells are relatively resistant to some acute injuries. A 2016 study found that certain melanopsin-positive cells maintained mammalian target of rapamycin activity after optic nerve injury. Yet the same research also found that native melanopsin-positive cells did not themselves show the robust regeneration seen in some alpha cells after growth-promoting treatments. Survival and regeneration are related, but they are not interchangeable. ()
Glaucoma adds another complication. It is not a one-time crush: it is generally a chronic disease in which damage unfolds over time. Some studies suggest that specific retinal ganglion cell types, including some alpha OFF-transient cells, may be more vulnerable than others. Melanopsin-positive cells may be relatively preserved in some animal and human samples, but human evidence is limited, and not all melanopsin-cell subtypes respond the same way. The OPN4 approach could therefore act strongly on cells tha
Support the show
A Steroid Injection During Glaucoma Surgery Was Linked to Dangerous Low Eye Pressure — What a New Randomized Trial Found
2026/11/04
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/a-steroid-injection-during-glaucoma-surgery-was-linked-to-dangerous-low-eye-pressure-what-a-new-randomized-trial-found
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
A Steroid Injection During Glaucoma Surgery Was Linked to Dangerous Low Eye Pressure — What a New Randomized Trial Found
Research checked through November 4, 2026.
A small randomized trial published on October 29, 2026, raised a serious safety question: could a long-acting steroid injection given during glaucoma drainage-device surgery suppress healing so much that the eye drains too freely? In the trial, late-onset low eye pressure occurred in 10 of 19 eyes given triamcinolone around the implant, compared with none of 20 control eyes. Seven of the 10 affected eyes needed another operation.
That is a striking signal—but it does not show that ordinary steroid eye drops after glaucoma surgery are dangerous, nor that every drainage device or steroid regimen carries the same risk. The study tested one 20-milligram depot injection with one non-valved implant, in a small group of people with difficult-to-control glaucoma. Important details about the pressure threshold, the timing of individual cases, and their recovery are not reported in the publicly available abstract or registry. Trial report on PubMed Trial record on ReBEC
What the new randomized trial tested
Treatment, injection location, and masking
The study included 39 eyes from 39 people with refractory primary open-angle glaucoma. All were undergoing Susanna UF glaucoma drainage-device surgery; the registry says participants had failed at least one prior trabeculectomy. Twenty eyes were assigned to the device alone, and 19 to the device plus triamcinolone. Follow-up lasted six months. The journal describes the study as multicenter and randomized. Trial report on PubMed Trial record on ReBEC
The triamcinolone was 20 milligrams: 0.5 milliliters of a 40-milligram-per-milliliter suspension. It was injected into the sub-Tenon’s space around the implant plate, immediately before the conjunctiva—the tissue covering the white of the eye—was closed. This is a depot injection beside the implant, not an injection into the inside of the eye. Trial record on ReBEC
The published abstract says that patients and outcome assessors were masked. The registry says a sham injection might have been used to mask the surgeon, but also allows that no sham was performed. So, based on the public records, surgeon masking cannot be confirmed. The registry also does not provide the full surgical recipe: it does not establish whether the tube was tied, fenestrated, or internally stented, or whether mitomycin C was used. Those details matter because they can change how much fluid flows through the device. Trial report on PubMed Trial record on ReBEC
There are two further cautions. The registry lists a target of 48 participants, but only 39 were enrolled; recruitment stopped early because of safety concerns. It also records a first enrollment date in December 2020 and a public registration date in July 2025. Late public registration does not prove that results were reported selectively, but it limits confidence that every outcome and analysis was publicly specified before enrollment began. All 39 enrolled participants completed six-month follow-up. Trial record on ReBEC
What the trial found
For the full table, please open this article on visualfieldtest.com.
The injection did not provide an additional pressure-lowering benefit at six months. Average pressure was about 14 mmHg in both groups, and the reduction from baseline was almost identical. A similar group average does not rule out serious low-pressure episodes in individual eyes: averages can hide a wide range of outcomes. Trial report on PubMed
The seven operations were performed in seven of the 10 eyes with late-onset hypotony. The public report does not say what procedures were used, when each operation occurred, or whether each eye’s pressure and vision ultimately recovered. Trial record on ReBEC
What is—and is not—known about the complications
The registry reports these additional events:
For the full table, please open this article on visualfieldtest.com.
The registry defines a serious-complication group as late hypotony or malignant glaucoma. That composite was 52.6% in the triamcinolone group and 5% in controls. The single control event was malignant glaucoma; it was not a case of late hypotony. The published abstract separately reports late hypotony as 10 of 19 versus zero, and clinically significant hypotony requiring reintervention as seven of 19 versus zero. Trial report on PubMed Trial record on ReBEC
The public abstract and registry do not give an exact numerical definition of hypotony or the threshold used to label an event “late-onset.” They also do not give the month each case began or how long it lasted. The registry reports no statistically significant difference in average visual acuity at follow-up, and no event directly related to the intervention led to loss of light perception. But it does not report how many individual patients lost lines of vision, or provide separate counts for choroidal detachment, hypotony-related macular changes, shallow front chamber, or bleb leaks. Those outcomes should be treated as not reported, not as confirmed zero events. Trial record on ReBEC
The registry says that de-identified participant-level data may be requested from the investigators, subject to a research proposal and ethics approval. That dataset would be needed to learn the exact case timelines and individual outcomes. Trial record on ReBEC
Why might a steroid depot lead to too much drainage?
The capsule around an implant helps regulate flow
A drainage device carries fluid from inside the eye to tissue around its plate. As healing proceeds, a fibrous capsule forms around that plate. The capsule is not merely scar tissue to eliminate: it also provides much of the resistance that regulates drainage. Too much scarring can restrict flow and raise eye pressure; too little capsule resistance can allow excessive flow and lower pressure too far. American Academy of Ophthalmology overview of drainage devices
Evidence supports the general pathway, but not the precise explanation for this trial. A broad review describes how inflammation and fibroblast activity contribute to wound healing and scarring after glaucoma surgery. A separate report described three patients on long-term systemic immune-suppressing treatment who developed persistent hypotony after non-valved implants; their implant capsules were thin and immature. That makes it biologically plausible that strong suppression of healing could reduce capsule resistance. But those cases involved chronic systemic treatment, not a one-time 20-milligram injection of triamcinolone around a Susanna device. The Susanna trial did not measure capsule thickness or fluid flow. Wound-healing review Capsule histology case report
The most plausible explanation is therefore an inference: if the depot reduced inflammation and capsule formation around the plate, the outflow pathway may have had less resistance. That could lead to excess drainage, especially once any temporary restriction on tube flow weakens or opens. The trial’s public records do not establish the timing of hypotony relative to tube opening, or even the exact tube-restriction method used. So this mechanism is reasonable, but unproven for these eyes.
A depot is not the same as adjustable eye drops
A depot injection leaves a suspension near the implant that releases medicine over time. A study of sub-Tenon’s triamcinolone after cataract surgery describes drug delivery lasting several weeks, though the duration can vary. In contrast, eye drops deliver a dose with each use; clinicians can taper or stop them based on the eye’s inflammation and healing. Randomized study of 20-milligram sub-Tenon’s triamcinolone after cataract surgery
Crucially, both arms in the Susanna trial received postoperative dexamethasone eye drops—initially six times a day, then gradually reduced over six to eight weeks. The randomized difference was the added depot injection. The trial therefore does not show that routine postoperative steroid drops caused the hypotony signal. It tested a long-acting injection on top of the same drop regimen given to controls. Trial record on ReBEC
Steroids can also raise eye pressure in some patients, particularly with prolonged exposure. That is a different effect from the suspected mechanism here: the concern is not that triamcinolone directly lowers pressure inside the eye, but that it might change wound healing and reduce resistance around a drainage pathway.
How the findings compare with other glaucoma surgeries
For the full table, please open this article on visualfieldtest.com.
Why the results may differ
Valved versus non-valved devices. The Ahmed valve is designed to restrict flow as pressure becomes low. Susanna UF and Baerveldt implants are non-valved, so they lack that same built-in valve. Non-valved implants are commonly managed with temporary tube ligatures, stents, or other flow-control steps, but the Susanna trial’s public records do not say exactly which were used. In a pooled analysis of three randomized tube-surgery trials, chronic hypotony was uncommon overall—4.1% by five years—but the risk was higher
Support the show
Could Eye Blood-Flow Scans Predict Glaucoma Progression Better Than Regular OCT? New 4-Year Results
2026/11/02
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/could-eye-blood-flow-scans-predict-glaucoma-progression-better-than-regular-oct-new-4-year-results
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Could Eye Blood-Flow Scans Predict Glaucoma Progression Better Than Regular OCT? New 4-Year Results
Short answer: Optical coherence tomography angiography (OCTA) may reveal glaucoma-related change when conventional retinal thickness measurements are no longer changing clearly—especially in some eyes with advanced glaucoma. But the new study does not prove that OCTA is superior to structural optical coherence tomography (OCT). It found an association between faster vessel-density loss and visual-field progression; it did not make a formal comparison of how well the two tests predict progression, and important methodological details are not available in the abstract.
A key wording point: OCTA is not a direct blood-flow meter. It detects a signal from moving blood cells and maps vessels that are flowing fast enough to be detected. A falling vessel-density reading may reflect reduced flow signal, capillary loss, image quality, or a combination of these—not necessarily vessels physically disappearing. American Academy of Ophthalmology OCTA assessment
What the October 28, 2026 study found
The study, “Longitudinal OCT Angiography Versus Structural OCT for Predicting Visual Field Progression in Glaucoma,” was published in the Journal of Glaucoma on October 28, 2026. It followed 333 eyes with open-angle glaucoma, including 110 eyes with normal-tension glaucoma, for an average of 4.1 years. The reported results support OCTA as a potentially useful additional monitoring signal—but do not establish that it should replace OCT or visual-field testing. Journal of Glaucoma article record
What can—and cannot—be reconstructed
The study’s accessible abstract reports that it was a prospective study. The glaucoma eyes were followed quarterly; 60 age-matched healthy control eyes were examined at the start and again after six months. The researchers tracked:
Peripapillary capillary vessel density: the capillary signal around the optic nerve.
Macular vessel density: the capillary signal in the central retina, including the parafoveal area.
Peripapillary retinal nerve fiber layer thickness: a structural OCT measurement around the optic nerve.
Macular ganglion cell–inner plexiform layer thickness: a structural OCT measurement of retinal cells important to vision.
Visual-field progression: worsening in the patient’s measured field of vision.
The researchers compared change rates with linear mixed-effects models and used multivariable Cox models with cumulatively updated change rates as time-dependent predictors. Visual-field progression was described as being determined with combined event-based and trend-based criteria. Journal of Glaucoma article record
There is an important limit to what can be verified: the accessible abstract does not provide the scan device, exact visual-field criteria, glaucoma-stage definitions, full list of model adjustments, or all numerical results. It also does not give confidence intervals for the structural-OCT hazard ratios or the rates of change in the healthy controls. I could not verify those details from a full Methods section or supplement for this review. They should not be guessed.
The reported numerical results
For the full table, please open this article on visualfieldtest.com.
The macular vessel-density loss rates differed by 0.72 percentage points per year between progressors and nonprogressors; the peripapillary rates differed by 0.17 percentage points per year. The hazard ratios mean that, in the model, faster vessel-density loss was associated with a higher rate of visual-field progression. They do not tell a patient’s absolute chance of losing vision, and they do not show that a vessel-density change caused the field loss.
The retinal nerve fiber layer and ganglion-cell layer rates were not statistically significant independent predictors in the reported adjusted models. That does not prove that structural OCT is useless, nor does it prove OCTA is better. A significant result for one measure and a nonsignificant result for another is not, by itself, a formal statistical test that one test outperforms the other.
The abstract says the Cox models were multivariable, but it does not identify the adjustment variables. Therefore, it is not possible to confirm from the accessible report whether the vessel-density associations remained after accounting for blood pressure, age, glaucoma severity, signal quality, cataract, myopia, or other factors. Nor can the inclusion of 110 normal-tension glaucoma eyes establish a specific OCTA benefit for that subgroup: separate normal-tension results are not provided in the abstract. Journal of Glaucoma article record
Why OCTA may add information when structural OCT appears flat
Structural OCT can reach a measurement floor
Structural OCT measures tissue thickness. In advanced glaucoma, the retinal nerve fiber layer can become so thin that much of the remaining signal comes from non-neural tissue, such as glial tissue and blood vessels. Further nerve-cell damage may then produce little measurable change in the thickness number—a measurement floor.
The floor varies by device and measurement method. In one advanced-glaucoma study, average peripapillary nerve fiber layer measurements reached an estimated floor around a visual-field mean deviation of −17.5 decibels, while some macular vessel-density measures remained measurable at more severe field loss. Other studies have found that some macular ganglion-cell tissue remains above its floor in parts of the retina even when the peripapillary nerve fiber layer is near its floor. So the practical point is not that all structural OCT fails in advanced disease: macular ganglion-cell measurements may continue to help, depending on the eye and the region measured. OCT/OCTA floor study Structural OCT floor study
Vessel-density measures may retain a signal deeper into disease—but are not floor-proof
Some OCTA measurements have shown a longer usable range into severe disease than thickness measurements. In one analysis, parafoveal vessel density had no detectable floor within the study’s observed range, while structural nerve fiber and ganglion-cell measures showed floors at less severe visual-field loss. But a different study found that OCTA measures often had fewer reliable measurement steps across their full range than structural OCT measures, partly because OCTA has its own test–retest variability. The result is a trade-off: OCTA may remain measurable later, but that does not automatically make it easier to detect a small, genuine change. OCTA and OCT measurement-floor comparison OCTA measurement-floor study
The scan measures a vascular signal, not the health of a nerve cell directly
OCTA can show a change in capillary signal in a retinal region where thickness values are stable. That may be useful because retinal ganglion cells and their nerve fibers depend on blood supply, and capillary signals can change without a measurable change in the thickness of the tissue being scanned.
But OCTA does not directly measure oxygen delivery, blood-flow volume, or whether each nerve cell is alive. A reduction in its signal may occur because flow has slowed below the instrument’s detection threshold, because capillary pathways have changed, or because of image artifacts. A “vessel-density loss” should therefore be read as a change in the scan’s flow-related vascular signal—not as a literal count of vanished blood vessels. American Academy of Ophthalmology OCTA assessment
Do vascular changes cause nerve damage, or follow it?
Both explanations are plausible, and current clinical imaging studies do not settle the question.
Hypothesis 1: reduced or unstable blood supply contributes to nerve injury
The retina and optic nerve need a steady supply of oxygen and energy. If blood supply becomes inadequate or poorly regulated, nerve cells may be more vulnerable to stress. Blood-pressure changes, low ocular perfusion pressure, and impaired vascular autoregulation have all been investigated in glaucoma. A vascular contribution could be particularly relevant in normal-tension glaucoma, where damage occurs even without a high measured eye pressure.
Longitudinal studies showing vessel-density change before later visual-field change fit this hypothesis, but they do not prove it. An earlier scan change may indicate that vascular stress is part of the disease process—or simply that the vascular measure detects damage earlier than a later test. Review of the retinal neurovascular unit in glaucoma American Academy of Ophthalmology Preferred Practice Pattern
Hypothesis 2: damaged nerve cells need less blood
The opposite direction is also reasonable: if retinal nerve cells are damaged or less active, they may need less energy and therefore less blood supply. Capillary signals could decline because the neural tissue is already deteriorating. Under this explanation, OCTA is an indirect marker of injury rather than a cause of it.
Most likely: the relationship is mixed and may run both ways
The evidence is consistent with a coupled process: vascular regulation and nerve-cell health may influence one another, while glaucoma and other patient factors affect both. Importantly, a scan showing a vascular
Support the show
Once Glaucoma Starts Progressing, How Hard Is It to Stop? A New 12-Year Study Gives an Answer
2026/10/29
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/once-glaucoma-starts-progressing-how-hard-is-it-to-stop-a-new-12-year-study-gives-an-answer
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Once Glaucoma Starts Progressing, How Hard Is It to Stop? A New 12-Year Study Gives an Answer
A first confirmed visual-field progression event is a warning—not a guarantee that vision will keep worsening. But a large, long-running study from Bascom Palmer Eye Institute suggests that a meaningful share of eyes do progress again, even while receiving routine care.
Published online in JAMA Ophthalmology on October 22, 2026, the study found that recurrence was more likely when vision had been declining quickly before the first event and when average eye pressure remained higher afterward. More pressure reduction was associated with less recurrence, but this was an observational study: it cannot prove that treatment escalation caused the difference. ()
What the Bascom Palmer study measured
Researchers reviewed records from 7,457 eyes belonging to 5,086 people with open-angle glaucoma or suspected glaucoma. The records spanned 1998 to 2025. Across the full group, average follow-up was 12.4 years, with an average of 12.3 visual-field tests per eye. A visual-field test measures how well a person sees in different parts of their field of vision.
The first progression analysis included all 7,457 eyes. The recurrence analysis was narrower: 1,951 eyes had an initial “likely progression” event, but only 635 had enough later visual-field tests and eye-pressure records for the researchers to assess recurrence. The recurrence results therefore describe this smaller, well-monitored group—not every eye in the original registry. ()
How the study defined a progression event
The researchers used Guided Progression Analysis, a tool for comparing visual-field test results over time. It compares later tests with the average of the first two reliable tests and looks for worsening at the same test locations beyond the amount expected from normal test-to-test variation.
An eye met the study’s definition of “likely progression” when three or more of the same locations worsened on three consecutive examinations. The event was dated to the first of those three examinations. This is a repeatable, computer-based signal—not a guarantee that every flagged change represents irreversible glaucoma damage without any possible test or eye-health influence. ()
To look for a second event, the researchers reset the comparison: the first progressing visual field and the next examination became the new baseline tests. They then reapplied the same progression rule to the remaining tests. The recurrence analysis required at least four visual-field tests after the first progressing examination. ()
How often did progression recur?
Across the full cohort, 1,951 of 7,457 eyes—26.2%—had an initial likely-progression event. Among the 635 eyes with enough subsequent testing and pressure data, 167—26.3%—had a recurrent event during the follow-up available to the study. ()
The researchers also used a time-to-event method that accounts for eyes having different lengths of follow-up. Its estimated cumulative recurrence was:
For the full table, please open this article on visualfieldtest.com.
At the 3-year mark, the 95% confidence interval was 11.6% to 17.1%; at 5 years, it was 22.1% to 29.5%; and at 10 years, it was 35.8% to 52.1%. The number at risk fell from 635 at the start to 30 at 10 years; it was 578 at 2 years, 382 at 4 years, 151 at 6 years, and 45 at 8 years. The 10-year estimate is therefore much less precise than the earlier estimates. ()
These numbers are not contradictory: 26.3% is the share of the 635 eyes with a recurrence recorded during their available follow-up. The 43.5% figure is the estimated cumulative chance by 10 years, accounting for differences in follow-up time. It does not mean that 43.5% of all 7,457 eyes recurred. The paper also notes that recurrence was recorded more often in the 635-eye analysis than in the broader group of eyes with initial progression—26.3% versus 15.2%—in part because eyes without enough later tests could not register a recurrence. ()
Which eyes were more likely to progress again?
The strongest signal was how quickly the visual field had already been worsening. In the study’s adjusted analysis, each 1-decibel-per-year faster loss in mean deviation—a summary measure of visual-field damage—was associated with a 73% higher hazard of recurrence. “Hazard” describes the relative rate of a new event over time; it is not the same as an individual’s absolute probability of recurrence. ()
Other adjusted associations included:
Higher average eye pressure after the first event: each additional 1 millimeter of mercury was associated with a 9% higher recurrence hazard.
Greater pressure reduction: each additional 10% of reduction from the pre-event average was associated with an 11% lower hazard. The pressure level and percentage reduction were analyzed in separate models because they were related; they should not be added together as if they were independent effects.
Older age: each additional five years was associated with roughly an 8% to 11% higher hazard, depending on the model.
Visual-field damage at the first event: eyes with a less negative mean-deviation score—generally less advanced loss—had a higher measured recurrence hazard. The authors cautioned that progression can be harder to detect in advanced disease because damaged test locations have less remaining range to worsen. ()
The study’s combined prediction model had moderate, not high, ability to distinguish which eyes would recur. It is a useful risk signal, not a validated calculator for an individual patient. ()
Fast progressors stood out
Among 96 eyes losing more than 1 decibel per year before the first event, 42.7% had recurrent progression, compared with 23.4% of slower-progressing eyes. The difference was about 19 percentage points. ()
This does not mean that every fast-progressing eye will worsen again, or that every slower-progressing eye is safe. It does mean that the earlier rate of change contains important information: a first progression event in an eye that was already losing field quickly deserves particular attention.
What happened to fast-progressing eyes after the first event?
The study compared the change in mean-deviation slope for fast-progressing eyes that did and did not have a recorded recurrence:
Fast progressors without a recorded recurrence slowed from about −1.71 to −0.39 decibels per year after the first event.
Fast progressors with recurrence slowed less, from about −1.70 to −1.31 decibels per year.
The groups’ pre-event slopes were nearly identical. Afterward, the nonrecurrence group had a lower average pressure—14.0 versus 16.2 millimeters of mercury—and a pressure reduction greater than 20% was more common among them, 36.4% versus 12.2%. These are striking observations, but they do not establish why the groups’ courses diverged. ()
Does this show that stronger pressure lowering changed the disease course?
It is consistent with that possibility, but it is not proof. Pressure lowering is already supported by randomized trials as a way to reduce glaucoma progression. In the Bascom Palmer study, recurrence was also associated with higher post-event pressure, and eyes with a larger pressure reduction tended to fare better. But the study did not randomly assign people to different pressure targets or treatment plans. ()
Several other explanations could contribute:
Regression to the mean: an eye selected because it had a particularly steep prior decline or a triggering progression event may show a less extreme slope later, even without an effective treatment change. This is especially relevant when comparing a very fast pre-event period with the period afterward.
Treatment-selection bias: clinicians may intensify treatment for eyes thought to be at greatest risk. In observational data, treatment and disease severity are intertwined, and the direction of the resulting bias is not predictable.
Unknown treatment and adherence: the investigators did not have records of medication changes, laser treatment, surgery, or how consistently treatment was used. A lower recorded pressure could reflect any mix of treatment changes, improved adherence, or ordinary variation.
Selection and follow-up: only 635 of the 1,951 eyes with initial progression had the post-event tests and pressure data needed for this analysis. Eyes that remain in care and receive more tests also have more opportunity for another event to be detected. Long-term estimates depend on assumptions about eyes that leave follow-up. ()
So the study supports a clinically plausible message—pressure reduction may help after progression is detected—but it does not show that a particular escalation caused the slowing seen in one subgroup.
What does the pressure after the event tell us?
The proportion of eyes with a recorded recurrence rose across the study’s categories of average post-event pressure:
For the full table, please open this article on visualfieldtest.com.
These are crude recurrence proportions by pressure category, not proof of a safe cutoff or a guarantee that a particular pressure prevents damage. The analysis found a graded association, but some eyes still progressed even when their recorded average was 12 millimeters of mercury o
Support the show
Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target?
2026/10/27
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/scientists-protected-glaucoma-nerve-cells-without-lowering-eye-pressure-could-mitochondria-become-the-next-treatment-target
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target?
Short answer: possibly—but the new study is a promising prevention result, not yet proof that mitochondrial treatment can restore vision after glaucoma damage is established.
The study at the center of this question was first published in Advanced Science on October 18, 2026. Researchers used adeno-associated virus serotype 2 to increase A-kinase anchoring protein 1, or AKAP1, in the retina. Treated mice retained more retinal ganglion cells, had better electrical responses, and showed stronger tracer labeling along the projection to the brain—even while their eye pressure remained elevated. The results support the idea of pressure-independent neuroprotection. They do not show that treatment lowered pressure, nor do they show that it rescued neurons after damage was already measurable. The October 2026 Advanced Science paper ()
That distinction matters. A treatment given before pressure injury may prevent cells from becoming dysfunctional or dying. A treatment given after visual function has declined would have to do something more: restore function in living but impaired cells, rebuild lost connections, or both. The study did not test that harder question.
What AKAP1 does
AKAP1 is a signaling scaffold, a protein that helps hold other signaling proteins in a useful place. It is normally attached to the outer membrane of mitochondria, the cell’s energy-producing structures. AKAP1 is not itself an energy-producing enzyme. Its importance is that it helps organize signals near the mitochondrion, where those signals can influence mitochondrial shape, stress responses, and survival.
One important partner is protein kinase A, or PKA. AKAP1 can anchor PKA close to mitochondrial targets, including the fission protein DRP1. PKA-mediated phosphorylation of DRP1 at a particular site—serine 637 in the mouse numbering used in this work—usually makes DRP1 less able to drive mitochondrial fission. The calcium-sensitive enzyme calcineurin can remove that phosphate, which can favor DRP1 activity and mitochondrial division. Earlier laboratory work found that loss of AKAP1 in mouse retina was associated with lower DRP1 phosphorylation, more fragmented mitochondria, abnormal respiratory-chain proteins, and signs of oxidative and cell-death stress. The earlier retinal AKAP1 study ()
Mitochondria need both fusion and fission. Fusion can help mitochondria share contents and maintain function. Fission helps separate damaged parts, support mitochondrial transport, and allow quality-control processes such as mitophagy. The goal is not simply “more fusion.” It is a healthy balance that changes appropriately with a cell’s needs.
AKAP1 is also linked to OPA1, a protein on the inner mitochondrial membrane that helps govern fusion and the structure of the folds called cristae. But the new study did not show that AKAP1 physically binds OPA1. It showed that OPA1 levels changed along with AKAP1 treatment. The direct mechanistic case is stronger for the AKAP1–PKA–DRP1 relationship than for any direct AKAP1–OPA1 interaction.
Mitochondria also help manage cellular calcium and supply energy for processes such as nerve signaling and the release of neurotransmitters. It is therefore biologically plausible that mitochondrial stress could affect both calcium-sensitive signaling and synaptic performance. But in the new study, calcium handling was not directly measured, and the investigators did not establish that AKAP1’s synaptic effects were caused by restoring a particular calcium pathway. The authors themselves note that they did not measure PKA catalytic activity, recruitment of PKA to mitochondria, or formation of the AKAP1–PKA complex. ()
Is AKAP1 reduced in people with glaucoma?
Not in the new October 2026 study: that study is based on mouse models and cultured retinal cells, not human donor retina. Its central experiments do not establish how AKAP1 changes in human glaucoma.
There is, however, relevant human-tissue evidence in a separate study. In a small postmortem series, AKAP1 staining was lower within retinal ganglion-cell bodies from glaucoma donors. The overall retinal signal was not simply lower: AKAP1 staining was higher in some broader retinal measurements, apparently because AKAP1 was also increased in Müller glial cells. In other words, the answer depends on which cell type and which retinal region are measured. The human evidence is encouraging, but it is small, cross-sectional, and cannot tell whether the AKAP1 change caused degeneration or occurred in response to it. Related study including human donor retina ()
FACT: A separate small human-tissue study reports lower AKAP1 signal in glaucoma retinal ganglion-cell bodies.
STRONG INFERENCE: AKAP1 may be relevant to human disease, but it is not yet established as a consistently reduced, causal driver across glaucoma patients.
What the October 2026 study actually did
The researchers used two mouse models and a set of cell-culture experiments. The treatment was a viral vector carrying mouse Akap1 under a broad cytomegalovirus promoter. The vector was not restricted to retinal ganglion cells; other retinal cells could also receive it.
DBA/2J spontaneous glaucoma
DBA/2J mice develop glaucoma as they age. The researchers injected the vector into the vitreous of 5-month-old mice and assessed them at 10 months. Age-matched DBA/2J-Gpnmb-positive mice, which do not develop the same glaucoma phenotype, served as non-glaucomatous controls.
Only DBA/2J mice with recorded intraocular pressure between 20 and 35 millimeters of mercury were included in the glaucoma analyses. Across the screening cohort, 64 of 98 10-month-old DBA/2J mice had confirmed pressure elevation. The methods report peak-pressure averages of 21.5 ± 4.5 millimeters of mercury in right eyes and 19.9 ± 3.7 millimeters of mercury in left eyes for the glaucoma-mouse cohort; these are not presented as the treatment-versus-control means for the specific vector comparison. ()
The authors report that AKAP1-treated DBA/2J mice had:
More retinal ganglion cells in both middle and peripheral retinal regions than glaucoma mice given the null vector.
More cholera toxin B tracer labeling in the superior colliculus, a brain region receiving retinal input.
Higher pattern electroretinogram and pattern visual evoked potential amplitudes.
No improvement in pattern visual evoked potential latency.
The vector increased retinal AKAP1 and also increased PKA abundance. The paper reports the main outcomes as statistically significant, but the searchable article text does not give exact group means or percentage improvements for the plots. The figure legends supply sample sizes: 20 mice per group for the pressure panel; 9–18 retinas or mice for retinal ganglion-cell counts; 10 mice per group for electrical responses; and three mice for the superior-colliculus tracer analysis. ()
Microbead-induced ocular hypertension
In the second model, beads were placed in the front of the eye to obstruct fluid outflow and raise pressure. The article’s results section describes vector injection in 3-month-old mice, three weeks before the bead injection. The methods section, however, describes 6-week-old mice being injected with vector before bead administration. This age discrepancy is an internal reporting inconsistency. It does not change the key timing point: the vector was given before ocular hypertension was induced.
The bead model produced sustained intraocular pressure in the reported range of 20–30 millimeters of mercury for at least eight weeks. Pressure monitoring did not show a statistically significant difference between AKAP1-vector and null-vector groups. Compared with null-vector mice, AKAP1-treated mice retained more retinal ganglion cells, had better pattern electroretinogram and pattern visual evoked potential amplitudes, and had shorter—more normalized—pattern visual evoked potential latency. The figure legend reports 12–14 mice per group for pressure monitoring and electrical responses, and 7–10 retinal wholemounts per group for retinal ganglion-cell counts. ()
The researchers also tested pressure-stressed retinal ganglion cells in culture. Cells were transduced with the vector before exposure to elevated hydrostatic pressure or paraquat, an oxidative stressor. AKAP1 improved cell viability and oxygen-consumption measures under stress. This is useful mechanistic support, but it is another pre-injury treatment experiment, not a rescue experiment.
What the paper does—and does not—quantify
The paper reports directions and statistical significance for many plotted outcomes, but the full-text prose and figure legends do not provide exact numerical means, standard deviations, or percentage changes for most of the outcomes listed below. I have not inferred precise bar heights from figures or invented values.
For the full table, please open this article on visualfieldtest.com.
The full study gives the sample sizes and qualitative results, but not an accessible numeric table of all plotted outcome values. That limits independe
Support the show
Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained
2026/10/18
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/could-cataract-surgery-give-you-a-glaucoma-drug-that-lasts-for-years-the-bimatoprost-releasing-lens-explained
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained
Potentially—but not for everyone, and not as a cure for glaucoma. SpyGlass Pharma’s investigational Bimatoprost Drug Pad–Intraocular Lens System, or BIM-IOL, combines an artificial cataract lens with two small drug-releasing pads. The lens is designed to release bimatoprost, a pressure-lowering medicine, for about three years.
The early results are striking: in a randomized trial, roughly 96% to 98% of evaluable patients who received the drug-releasing lens were not using additional pressure-lowering drops at 12 months. A much smaller first-in-human study found that 20 of 21 participants followed for three years remained drop-free.
Those results make the idea worth taking seriously. But “drop-free” is not the same as “glaucoma-free,” and the strongest three-year result comes from a small, uncontrolled study—not the larger randomized trial. This article reviews the evidence available as of October 18, 2026, including the latest American Academy of Ophthalmology meeting presentation. The BIM-IOL remains investigational and not approved by the United States Food and Drug Administration. AAO 2026 results coverage ()
What Is the SpyGlass Bimatoprost Drug Pad–Intraocular Lens?
During cataract surgery, the cloudy natural lens is removed and replaced with an intraocular lens. The SpyGlass system uses a monofocal artificial lens with two bimatoprost-containing pads attached near the junction between the lens’s clear center and its supporting arms. The lens and pads are placed inside the eye’s capsular bag, where the natural lens used to sit.
The pads are positioned outside the main visual area and are designed to release bimatoprost slowly. Unlike an implant placed in the eye’s drainage angle, the BIM-IOL is intended to leave that angle available for future glaucoma procedures. Adding the pads requires preparation of the lens but is intended to fit within a routine cataract-surgery workflow. Published three-year pilot study ()
The system is designed to deliver medication for three years. That is a design goal supported by laboratory release testing and early human pressure measurements—not yet proof that every patient will receive three full years of effective treatment.
What Did the AAO 2026 Presentation Report?
At the American Academy of Ophthalmology annual meeting in New Orleans, held October 9–12, 2026, investigator Fiaz Zaman presented 12-month results from SpyGlass’s randomized Phase 1/2 trial. The trial enrolled people with a cataract and either mild-to-moderate open-angle glaucoma or ocular hypertension. AAO 2026 presentation coverage ()
Trial groups and pressure results
A total of 104 people were randomized:
For the full table, please open this article on visualfieldtest.com.
All participants stopped their existing pressure-lowering treatment for a washout period before the baseline measurements. The exact group mean washout pressures were not included in the public AAO report I could verify. Dividing the reported pressure reductions by the rounded percentages gives an approximate baseline of about 25–27 mmHg, depending on group and measurement time. These are calculated estimates, not separately published baseline figures. AAO 2026 results report ()
The lower-dose group had a numerically larger reduction than the higher-dose group. That does not establish that 39 micrograms is better: these reported averages do not demonstrate a clear dose-response relationship, and the small groups are not a definitive dose comparison.
How many patients were off pressure-lowering drops?
At 12 months, the presentation reported that:
98% of patients in the 78-microgram group were off additional pressure-lowering medication.
96% of patients in the 39-microgram group were off additional pressure-lowering medication.
Control-group participants were not reported as drop-free in the same sense: they were still using their assigned twice-daily timolol.
The company has summarized the combined treated groups as approximately 97% off topical pressure-lowering therapy at 12 months. “Medication-free” here means free of additional pressure-lowering eye drops; patients in the BIM-IOL groups used artificial tears as part of the trial and still received ordinary postoperative eye care. AAO 2026 report and SpyGlass Phase 1/2 results ()
Vision, corneal cells, and adverse events
The reported visual outcomes were reassuring:
All evaluable eyes in all three groups achieved best-corrected distance vision of 20/32 or better.
Vision of 20/20 or better was reported in 74% of the 78-microgram group, 65% of the 39-microgram group, and 63% of the control group.
Average vision across groups was about 86 letters, roughly equivalent to 20/20 vision.
The presentation also reported corneal endothelial cell density, a measure of the health of the cells lining the inside of the cornea:
For the full table, please open this article on visualfieldtest.com.
The investigators characterized the overall safety profile and endothelial-cell loss as comparable to routine cataract surgery. However, the numerically larger decline in the smaller 39-microgram group deserves follow-up. These are calculations from reported group averages; the public conference coverage does not provide a full adjusted comparison or enough detail to interpret the differences confidently. AAO 2026 safety and vision results ()
Any adverse event was reported in 21 people in the 78-microgram group (41%), 10 in the 39-microgram group (43%), and 11 in the control group (37%). The report described no serious adverse events, secondary surgical interventions, or lens explantations through 12 months. The public report does not provide a complete event-by-event breakdown, so the overall percentages should not be read as the proportion who had a problem caused by the drug pads. ()
How Meaningful Is a 96–98% Drop-Free Result?
It is a meaningful early signal. If confirmed in larger and longer studies, avoiding daily pressure-lowering drops could reduce the burden of remembering, handling, and paying for them. That could matter especially for people who struggle with daily dosing.
But the headline needs context.
It does not mean 98% of patients stopped drops they were taking
About one-third of trial participants were taking no pressure-lowering medication at screening. They may have had elevated pressure without current treatment, or they may have been suitable for observation under their clinicians’ care. So the reported drop-free percentage is not the same as saying that 96–98% of people who had been using drops successfully stopped them after surgery. The report does not provide enough detail to calculate that specific number. AAO 2026 study details ()
The control group also had a large pressure reduction
The control group had ordinary cataract surgery, received a standard lens, and used timolol. Its reported pressure reduction—about 35% at 12 months—was close to the reductions in the drug-pad groups. This trial therefore supports the idea that the BIM-IOL can maintain pressure control while avoiding assigned timolol drops; it does not show that the BIM-IOL lowered pressure more than the control treatment.
Cataract surgery itself can lower pressure, especially when the starting pressure is high. Estimates differ depending on the patients studied and whether pressure-lowering medications were stopped before measurement. A 2024 review of cataract-surgery trials found a 12-month average reduction of about 3.8 mmHg overall, with a larger average reduction in studies that used a medication washout. Cataract-surgery meta-analysis ()
“Drop-free” is not the same as “glaucoma controlled for life”
The Phase 1/2 trial reported eye pressure, vision, medication use, and safety. It did not establish that the lens prevents future visual-field loss, stops optic-nerve damage, or removes the need for future glaucoma care. The 12-month results are also interim data presented at a medical meeting; the available report is not a full peer-reviewed paper with all trial details.
Bottom line: the result is promising evidence of a strong chance of being free from additional pressure-lowering drops at one year in this selected study group. It is not yet proof that most people having cataract surgery can avoid glaucoma treatment indefinitely.
Does the Pressure-Lowering Effect Really Last Three Years?
The most direct human evidence comes from a small, prospective, nonrandomized first-in-human study in Honduras. The published paper says 24 people consented; company materials have described 23 people assigned to dose groups. Twenty-one were followed through 36 months. The study tested older configurations containing 75, 150, or 300 micrograms of bimatoprost—not the 39- and 78-microgram doses in the later randomized trial. Published three-year pilot study and company 36-month results ()
At 36 months, the reported average pressure for evaluable participants had fallen from 25.1 ± 2.5 mmHg after washout to 15.9 ± 2.7 mmHg, a reduction of about 37%. Twenty of 21 participants were still free of topical pressure-lowering medication. All 21 had at le
Support the show
Do Alcohol and Smoking Increase Glaucoma Risk? A New 9,418-Person Study Finds a Stronger Link
2026/10/17
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/do-alcohol-and-smoking-increase-glaucoma-risk-a-new-9-418-person-study-finds-a-stronger-link
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Do Alcohol and Smoking Increase Glaucoma Risk? A New 9,418-Person Study Finds a Stronger Link
A study published on October 10, 2026, reports that alcohol use and cigarette smoking were more common among people with primary open-angle glaucoma in a large African clinic-based sample. The headline figures are striking: former drinkers had about 49% higher odds of glaucoma, and current smokers about 46% higher odds.
But the details complicate the headline. This was a cross-sectional, clinic-based study, not a study that followed healthy people to see who later developed glaucoma. Most cases came from glaucoma clinics, while most controls came from cataract or general medical clinics. The researchers measured recent substance use, not lifetime exposure. And when former drinkers were excluded, the association between current drinking and glaucoma was no longer statistically clear.
My overall reading: heavy or repeated binge drinking may modestly contribute to glaucoma risk, but the evidence is not conclusive. The case that cigarette smoking causes glaucoma to develop is weaker. Smoking may, however, speed up structural damage in people who already have glaucoma; that possibility has some direct but limited evidence.
The new Eyes of Africa study: what it found
The Eyes of Africa analysis included 9,418 people aged 40 or older: 5,189 with primary open-angle glaucoma and 4,229 controls. Participants were enrolled from 2017 through 2023 at 16 centers in Nigeria, Ghana, and Malawi. The researchers used structured interviews to ask about alcohol, tobacco, medications, and other substances, then used statistical models to estimate adjusted odds of being a glaucoma case. The Eyes of Africa alcohol-and-smoking study
How cases and controls were recruited
The sample was assembled mainly through eye-care clinics, rather than by randomly sampling the population:
98.6% of glaucoma cases came from glaucoma clinics; 1.4% came from community outreach.
93.1% of controls came from cataract clinics or general geriatric clinics; 6.9% came from community outreach.
The teams invited consecutive eligible patients, which helps avoid cherry-picking within those clinics—but does not make the clinics representative of the wider population.
That imbalance matters. It means the study’s odds ratios describe differences in this selected case-control sample; they are not direct estimates of how much an individual’s chance of developing glaucoma changes. Eyes of Africa study methods
How glaucoma was diagnosed
The study used the International Society of Geographical and Epidemiological Ophthalmology criteria. In everyday terms, a diagnosis required evidence of damage to the optic nerve, usually supported by a characteristic visual-field defect, an open drainage angle on gonioscopy, and no other eye condition that better explained the damage. In some severely damaged eyes where a usable visual-field test was not possible, advanced optic-nerve damage could support the diagnosis. Controls had no clinical evidence of glaucoma and an eye pressure below 22 millimeters of mercury. Eyes of Africa methods
The substance-use article itself does not report glaucoma severity or eye pressure by alcohol or smoking category. A companion report on the same cohort supplies useful context: cases averaged 63.9 years of age versus 61.4 for controls; 76.8% of cases had severe glaucoma in at least one eye at recruitment. Average eye pressure at study entry was 19.8 millimeters of mercury in cases, compared with 14.5 in hospital-based controls and 12.8 in community controls. The cases’ average historical maximum pressure was 24.9. These figures describe the overall cohort—not the drinking or smoking subgroups—and many cases were already receiving treatment. Eyes of Africa cohort profile
Age and social differences between groups
The glaucoma group was older. Among cases, 29.1% were 80 or older, compared with 21.7% of controls. Cases were also more often male, unemployed, and had completed secondary education or more. In the adjusted model, unemployment was associated with higher odds of being a case (1.23), as was secondary education or higher (1.27). These are social characteristics, not proof that unemployment or education causes glaucoma; they may also reflect differences in health, access to eye care, or diagnosis. Eyes of Africa study results
The reported alcohol and smoking figures
The study’s adjusted odds ratios, compared with never-users unless otherwise specified, were:
For the full table, please open this article on visualfieldtest.com.
The reported estimates are real, but they need careful interpretation. “Former drinker” meant no alcohol in the 30 days before the interview, not necessarily someone who had permanently quit after years of heavy drinking. “Current drinker” meant at least one drink in that 30-day period. “Former smoker” meant having smoked more than 100 cigarettes over a lifetime but not in the prior 30 days. These brief definitions do not tell us how much a person used to drink or smoke, for how long, or how long ago they stopped. Eyes of Africa exposure definitions and regression results
There is also an important detail about the “heavy episodic drinking” result. In the paper, the measure was the largest amount ever consumed in a single day: more than two drinks versus two or fewer. It did not measure how often this happened or the person’s lifetime total. It is therefore not a reliable measure of sustained heavy drinking, and it is not the same as a well-characterized dose-response analysis.
What the study did—and did not—show about dose
The study did not record lifetime alcohol units or smoking pack-years. Pack-years combine the number of cigarette packs smoked each day with the number of years smoked. Without these cumulative measures, the researchers could not test whether risk rose steadily with long-term exposure.
Among current drinkers, reported monthly consumption did not differ significantly between cases and controls. Among current smokers, the number of cigarettes smoked per day also did not differ significantly. Those comparisons were limited by small numbers at higher exposure levels. The study therefore offers no clear dose-and-frequency curve for either substance. Eyes of Africa alcohol and tobacco patterns
Two further results deserve attention:
In an analysis restricted to current and never-users, current drinking was not associated with higher glaucoma odds: adjusted odds ratio 0.90 (95% confidence interval 0.78–1.04). The alcohol signal in the main analysis was therefore substantially influenced by the former-drinker group.
In that restricted analysis, the association with current smoking remained: adjusted odds ratio 1.62 (95% confidence interval 1.16–2.27). This is still an association within a clinic-based sample, not proof of causation.
The team adjusted for age, sex, education, employment, country of birth, and other measured substance-use variables. It did not fully account in its main model for factors such as family history of glaucoma, eye pressure, central corneal thickness, myopia, or a detailed set of medical and vascular conditions. A supplementary model adding body mass index reduced the current-alcohol association until it was no longer statistically significant; the authors reported that several other associations changed less. Eyes of Africa adjusted results and limitations
Why do former drinkers look worse than current drinkers?
At first glance, the former-drinker result—an odds ratio of 1.49, compared with 1.15 for current drinkers—could seem to suggest that quitting alcohol increases glaucoma risk. That is not a sensible causal interpretation. Several other explanations are more likely.
Illness-related quitting and reverse causation
People may reduce or stop drinking after a diagnosis, after developing another illness, or when treatment or family circumstances change. If some glaucoma cases had already been diagnosed before the interview, their diagnosis could have influenced their drinking. Because glaucoma often develops unnoticed for years, it is difficult to know whether alcohol use preceded the disease, changed because of it, or both.
The Eyes of Africa study does not report when each person stopped drinking relative to glaucoma onset or diagnosis. Its cross-sectional design cannot sort out that sequence. The researchers themselves noted that people may have reduced drinking after diagnosis or health advice. Eyes of Africa discussion
The “former drinker” category combines very different people
A person who stopped drinking last week and a person who stopped decades ago are both “former drinkers” in this analysis. So are people who drank only occasionally and happened not to drink in the last 30 days. The category does not distinguish illness-related quitting from social, religious, financial, or other reasons for not drinking.
This broad grouping can make the former-drinker association difficult to interpret. It also leaves room for sick-quitter bias: people may quit because they are unwell, and their illness—not their quitting—may be associated with glaucoma or with clinic attendance.
Age, health, and survival could also contribute
Cases were older than
Support the show
A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In
2026/10/16
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-procedure-uses-donor-tissue-to-keep-the-eye-s-drainage-canal-open-first-human-results-are-in
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
A New Glaucoma Procedure Uses Donor Tissue to Keep the Eye’s Drainage Canal Open — First Human Results Are In
Short answer: The first results are encouraging, but they do not yet show that donor tissue makes canaloplasty more durable. The reported 52-eye study has no published full paper, no control group, and only six months of follow-up. Because the procedure was combined with cataract surgery, some—and possibly a substantial part—of the pressure drop may have come from cataract removal rather than the allograft.
The idea is plausible: open Schlemm’s canal, then support it with donor tissue. But the key claim—that this support prevents clinically important canal recoil and improves lasting pressure control—still needs a randomized comparison.
Evidence reviewed through October 16, 2026.
What the first 52-eye results show
On October 8, 2026, Iantrek announced preliminary six-month results from a first-in-human, single-center observational study of bio-reinforced canaloplasty combined with cataract surgery. The company reported outcomes for 52 treated eyes. The full study report was not published with the announcement; the data were described as “on file” and subject to further analysis. (Iantrek’s October 8 announcement, Ophthalmology Management’s report)
For the full table, please open this article on visualfieldtest.com.
The 14.1 figure is calculated, not separately published: 22.4 × (1 − 0.372) = 14.07. Because the baseline and percentage are rounded, the exact study mean might differ slightly. The medication calculation is also approximate: a 49.1% reduction from 1.2 medications implies a reduction of about 0.59, leaving an average of about 0.61.
These are the figures in the company announcement, not independently audited results. “No serious adverse events” does not mean there were no minor events, and a group of 52 eyes followed for six months cannot rule out uncommon complications or late problems.
Important study details are not yet public
The announcement does not provide enough information to establish several facts requested for a proper clinical assessment:
Glaucoma severity and subtype: Not reported for the 52-eye cohort.
Patient age: Not reported.
Previous selective laser trabeculoplasty or minimally invasive glaucoma surgery: Not reported.
Detailed inclusion criteria: Not reported.
Medication washout before baseline pressure measurement: Not reported. This matters: a pressure measured after stopping drops is not directly comparable with one measured while patients are taking them.
Cataract surgery: The study is described as bio-reinforced canaloplasty performed with cataract surgery. That implies the reported 52 eyes had combined surgery, but the press release does not provide a patient-by-patient study table.
Exact surgical steps: The type of dilation, how much of the canal was treated, and the precise graft-placement steps are not reported.
Allograft length and exact placement extent: Not reported for AlloSpan.
Postoperative eye-drop regimen: Not reported.
A separate, ongoing study called BOOST is registered as an observational study of bio-reinforced canaloplasty. Its registry describes placing minimally manipulated, homologous-use scleral allograft tissue in the wall region of Schlemm’s canal after canaloplasty. It targets 300 participants and plans two years of follow-up; it is not a randomized comparison of graft versus no graft. BOOST’s eligibility rules should not be assumed to describe the earlier 52-eye study. (BOOST study record)
What “bio-reinforced canaloplasty” means
The eye continuously produces clear fluid called aqueous humor. It normally drains through the trabecular meshwork, into Schlemm’s canal, and then through collector channels toward the veins around the eye. In open-angle glaucoma, pressure can rise when this drainage system does not carry fluid away efficiently.
Conventional canaloplasty
In conventional canaloplasty, a surgeon uses an instrument to enter and dilate Schlemm’s canal, commonly by delivering a viscoelastic fluid. Some versions also place a tensioning suture around the canal; other, newer ab-interno procedures do not. The goal is to stretch the canal and improve flow through the eye’s existing drainage route.
The proposed AlloSpan approach
Bio-reinforced canaloplasty adds another step: after dilating the canal, the surgeon places homologous donor scleral tissue in the canal-wall region to provide structural support. Public descriptions also characterize the platform as nitinol-guided and trabecular-meshwork-sparing, but the detailed steps used in the 52-eye study have not been published. (BOOST study record, Iantrek’s AlloSpan introduction)
The concept is therefore:
Conventional approach: Dilate the canal; hope the improved opening and flow persist.
Bio-reinforced approach: Dilate the canal, then add a biological scaffold intended to support its structure.
The word “reinforced” describes the intended mechanical role. It does not yet establish that the canal stays wider, that collector-channel flow improves, or that pressure control lasts longer.
Does Schlemm’s canal actually collapse or recoil after canaloplasty?
Canal narrowing is a real feature of eye anatomy. But current evidence does not establish that post-surgical recoil is a major cause of conventional canaloplasty losing effectiveness.
What imaging and tissue studies show
Anterior-segment optical coherence tomography studies have found that Schlemm’s canal can be larger after canaloplasty. One study documented increased canal dimensions during the first few months after surgery; another examined canal and trabecular-meshwork changes one year after combined cataract surgery and canaloplasty. Those studies support the idea that surgery changes the canal’s anatomy. They do not show that later pressure rises are caused by canal recoil, or that a graft prevents such rises. (Three-month imaging study, one-year phacocanaloplasty imaging study)
Laboratory and histological work also shows that the trabecular meshwork can bow toward—and narrow—the canal as pressure changes. But Schlemm’s canal is not simply an empty pipe. Its walls, internal supports, collector-channel openings, and surrounding tissues all respond to pressure. (Histopathological review of trabecular surgery, study of Schlemm’s canal and collector-channel anatomy)
Conventional canaloplasty can last for years without an allograft
Longer-term clinical results show that conventional canaloplasty can retain meaningful effects, although the evidence is mostly nonrandomized and outcomes vary. In a multicenter three-year study, the overall mean pressure was 15.2, while eyes having combined cataract surgery and canaloplasty averaged 13.6. In a separate ten-year observational study, mean pressure at ten years was 15.9 after canaloplasty alone and 14.2 after combined cataract surgery and canaloplasty. Medication use rose over time in some groups, suggesting that pressure lowering and medication reduction are not the same thing. (Three-year canaloplasty results, ten-year canaloplasty results)
These studies do not prove that canal anatomy never changes after surgery. They do show that a donor scaffold is not already known to be necessary for long-term canaloplasty benefit. A key missing link is evidence that patients whose canal later narrows are the same patients whose pressure control fails.
A larger canal may not solve all drainage problems
Even with a wider canal, fluid must still pass through the collector channels and other downstream tissues. Research suggests a substantial share of resistance can lie beyond Schlemm’s canal, in the collector-channel and venous pathways. So keeping the canal open could help, but it cannot necessarily fix blocked or poorly functioning downstream drainage. (Review of Schlemm’s canal procedures and outflow resistance)
How much of the pressure drop could cataract surgery explain?
This is the study’s biggest interpretive problem. AlloSpan was not tested against cataract surgery alone or against ordinary canaloplasty.
Cataract removal can lower pressure on its own, especially when the pressure before surgery is high. In the randomized HORIZON trial, patients with open-angle glaucoma had a medication-washout baseline mean pressure of about 24.5. At 24 months, the cataract-surgery-only group had an average pressure decrease of 5.3, about 22% of baseline. In an Ocular Hypertension Treatment Study analysis, cataract surgery was associated with a pressure decrease from a higher baseline, but the effect differed according to baseline pressure and medication use. (HORIZON trial report, Ocular Hypertension Treatment Study cataract analysis, analysis of cataract surgery in treated patients)
The AlloSpan announcement implies an overall decrease of about 8.3—from 22.4 to about 14.1. As a rough comparison:
If the 22.4 baseline was measured after medication washout, cataract-only results in a similar pressure range suggest cataract surgery might explain around 5 millimeters of mercury, or about 22 percentage points of the reported reduction.
If baseline was measured while patients were using their usual drops, the cataract-only contribution might be closer
Support the show
Can One Tiny Glaucoma Implant Replace Years of Eye Drops? New Randomized iDose TR Results
2026/10/15
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/can-one-tiny-glaucoma-implant-replace-years-of-eye-drops-new-randomized-idose-tr-results
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Can One Tiny Glaucoma Implant Replace Years of Eye Drops? New Randomized iDose TR Results
A small randomized trial reported a sizeable pressure reduction when iDose TR was added to cataract surgery: at three months, the combination group’s average daytime eye pressure fell by 11.1 millimeters of mercury, compared with 7.4 millimeters after cataract surgery alone. The company-reported difference between groups was 3.6 millimeters of mercury.
That comparison is the key result: because both groups had cataract surgery, it estimates the extra short-term reduction associated with adding iDose TR in this trial setting. But the public results are only a topline report. They do not provide the starting pressures, final average pressures, confidence intervals, responder percentages, or enough detail to separate the effect of cataract surgery from medication washout and other baseline changes. Nor do they show whether the additional reduction lasts one or three years.
Bottom line: iDose TR may reduce the need for daily drops for some people. The new trial supports an additional pressure-lowering effect at three months, but it does not yet show that an implant every few years can replace all drops—or postpone laser or glaucoma surgery over the long term.
The Phase 4 results were announced on October 9, 2026. As of October 15, 2026, the results were available as a company-released topline report, not a full peer-reviewed publication. (Glaukos/Business Wire release) ()
What GLK-101-04 tested
GLK-101-04 was a Phase 4 trial comparing iDose TR implanted during cataract surgery with cataract surgery alone. The official trial registry number is NCT06848946. (ClinicalTrials.gov record) ()
For the full table, please open this article on visualfieldtest.com.
The public registry gives only a limited account of eligibility. It lists active corneal inflammation or swelling and certain retinal disorders as exclusions. It does not report the trial’s glaucoma-severity distribution, baseline visual-field damage, or the prior laser and surgery history of the participants in the topline announcement. (ClinicalTrials.gov record) ()
What is not public yet
The topline release and registry do not provide the following information for GLK-101-04:
Medicated starting pressure and unmedicated starting pressure.
Whether pressure-lowering medicines were washed out before baseline, and, if so, how.
How many participants used one or more glaucoma medicines before the trial.
Detailed prior treatment history, such as selective laser trabeculoplasty or earlier glaucoma surgery.
How many participants had mild, moderate, or advanced glaucoma.
The group’s final average pressure at Month 3.
Exact responder rates at reductions of 20%, 30%, or 40%.
The percentages reaching pressure thresholds of 18, 15, 12, or 10 millimeters of mercury.
The treatment difference’s confidence interval or standard deviation.
A related earlier study of iDose TR used pressure-lowering medicine washout, but that does not establish that GLK-101-04 used the same rules. The new trial’s own public information is insufficient to confirm washout or reconstruct its baseline pressure. (Earlier iDose TR phase 3 report) ()
What the three-month results do—and do not—tell us
The company reported mean daytime pressure reductions from baseline of:
11.1 millimeters of mercury with iDose TR plus cataract surgery.
7.4 millimeters of mercury with cataract surgery alone.
A reported incremental treatment effect of 3.6 millimeters of mercury, with p0.0001.
The release says iDose TR was statistically superior across all prespecified secondary responder analyses, but it does not publish the responder thresholds or the percentage of eyes meeting them. (Glaukos/Business Wire release) ()
Can we calculate final pressures or percentage reductions?
No—not from the public numbers. A pressure reduction is not the same thing as a final pressure. If a group’s starting mean pressure were known, its final mean could be estimated by subtracting the reported reduction. But GLK-101-04’s starting group means have not been reported.
For the same reason, the percentage reduction cannot be calculated. It requires both the absolute decrease and the starting pressure. The company’s reported 3.6 millimeters of mercury is an absolute between-group difference, not a percentage reduction.
The release’s rounded reductions, 11.1 and 7.4, subtract to 3.7, while the company reports an incremental difference of 3.6. This small mismatch can arise when a treatment difference is calculated from unrounded statistical estimates and the displayed group changes are rounded. The release does not provide the unrounded values or analysis details needed to resolve it.
Effect size and confidence intervals
The reported 3.6 millimeters of mercury is the available absolute treatment effect. Relative to the 7.4-millimeter reduction reported in the surgery-alone group, it is about 49% larger. That is a descriptive comparison—not a standardized effect size, and not proof that the implant is 49% more effective than cataract surgery in general.
The release does not provide a confidence interval, standard deviation, or standard error. Therefore, neither a confidence interval nor a standardized effect size can be calculated responsibly from the public topline data. The reported p0.0001 indicates strong statistical evidence of a difference under the trial’s analysis, but it does not supply those missing quantities.
How much came from medication washout, surgery, and iDose TR?
The best-supported answer is:
iDose TR’s added effect: The randomized comparison suggests about 3.6 millimeters of mercury more reduction at Month 3 in the iDose-plus-surgery group than in the surgery-alone group.
Cataract surgery and other shared influences: The 7.4-millimeter reduction in the control group occurred after cataract surgery, but it cannot be assigned to surgery alone.
Medication washout and baseline effects: Their contribution cannot be determined because the public report does not disclose whether washout occurred or when baseline was measured in relation to medication use.
The 7.4-millimeter control-group decrease could reflect cataract surgery plus baseline conditions, medication changes, and other influences. A trial without a no-surgery group cannot isolate cataract surgery from all other changes. Research on cataract surgery alone in open-angle glaucoma has found a smaller average pressure reduction at 12 months in many studies, although results vary with starting pressure, use of medication washout, and study design. Those findings are useful context, but they cannot be used to reassign the components of GLK-101-04’s 7.4-millimeter change. (2024 systematic review; systematic review of cataract surgery and glaucoma) ()
Interpretation: the 3.6-millimeter between-group difference is the most relevant estimate of iDose TR’s added short-term effect in this trial. The full 11.1-millimeter reduction should not be described as the implant’s effect alone.
Why an extra 3–4 millimeters of pressure reduction can matter
Glaucoma damages the optic nerve and can cause permanent vision loss. Lowering eye pressure is the main proven way to slow that damage, but the pressure target must be chosen for the individual eye. A pressure that is adequate for one person may be too high for someone with more damage or faster progression.
In the Early Manifest Glaucoma Trial, each millimeter of mercury of lower pressure during follow-up was associated with roughly a 10% lower risk of progression. If that relationship were simply extended to a sustained 3–4-millimeter reduction, it would suggest a potentially meaningful reduction in relative risk. But that is a model-based extrapolation, not a finding that iDose TR itself has reduced visual-field progression by a specific percentage. The trial tested pressure at three months, not years of vision outcomes. (Early Manifest Glaucoma Trial analysis) ()
The Collaborative Normal-Tension Glaucoma Study also found less progression in treated eyes targeted for a 30% pressure reduction than in untreated eyes. That study involved a selected group of people with normal-tension glaucoma who already had documented progression or other high-risk features; its results cannot be applied mechanically to every person with glaucoma or ocular hypertension. (Collaborative Normal-Tension Glaucoma Study) ()
What it might mean for different pressure targets
These are clinical illustrations, not predictions of the final pressures in GLK-101-04. The trial has not reported the absolute starting or final group means, and an average group difference does not predict each individual’s response.
For the full table, please open this article on visualfieldtest.com.
The American Academy of Ophthalmology describes an initial treatment goal of reducing pressure by about 20% to 30% for many patients with primary open-angle glaucoma, then adjusting the goal for disease severity and response. A target is not a universal threshold, and a three-month pressure result does not replace ongoing checks of optic-nerve health and visual fields. (American Academy of Ophthalmology Preferred Practice Pattern) ()
How iDose TR compares with other trea
Support the show
First Human ER-100 Results: Did Epigenetic Reprogramming Actually Restore Some Vision in Glaucoma?
2026/10/12
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/first-human-er-100-results-did-epigenetic-reprogramming-actually-restore-some-vision-in-glaucoma
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
First Human ER-100 Results: Did Epigenetic Reprogramming Actually Restore Some Vision in Glaucoma?
Evidence cutoff: October 12, 2026.
Bottom line
Life Biosciences has reported an intriguing first human visual-field signal, but it has not shown that ER-100 restored lost vision. The company says that two of three people with open-angle glaucoma had more than a 4-decibel improvement at at least 28% of visual-field test locations at Day 56. On the registered test pattern, that is about 15 locations.
That is worth investigating. But the public report does not include the patients’ visual-field charts, their baseline measurements, repeat-test confirmation, global visual-field scores, or results from the untreated eyes. It also does not establish that the improvement occurred in previously damaged areas or that it reflects retinal ganglion-cell recovery rather than visual-field variability, learning, or another measurement effect.
ER-100 may be the first reported human signal for this partial-reprogramming approach. It is not the first human suggestion that some glaucomatous visual dysfunction can improve: earlier studies have reported improved retinal or visual-field measures after pressure reduction and other interventions. Nor do the three ER-100 cases establish that this particular treatment reversed damage.
For the full table, please open this article on visualfieldtest.com.
The main clinical facts come from Life Biosciences’ October 8 announcement and the trial registry. The company’s release reports the visual-field threshold; the registry describes the trial’s design and planned measurements. ()
What was actually disclosed
Treatment and follow-up
The October 8, 2026 announcement concerned three participants with open-angle glaucoma who received one intravitreal injection of ER-100 at Dose Level 1: 2 × 10¹¹ vector genomes in one eye. They took daily oral doxycycline for 56 days to induce expression of OCT4, SOX2, and KLF4, known together as OSK. The company also reported an oral prednisolone taper intended to reduce inflammation related to the adeno-associated virus type 2 vector. It did not disclose the steroid dose or taper schedule in the release. ()
The company said that visual-field improvement was observed in two of the three participants at Day 56. In both, at least 28% of visual-field locations showed an improvement of more than 4 decibels. The Data Safety Monitoring Board recommended moving to Dose Level 2, 6 × 10¹¹ vector genomes—three times the first dose. ()
The trial is open-label, non-randomized, and primarily designed to evaluate safety and tolerability. Its registry describes sequential dose escalation in glaucoma, followed by a separate cohort with non-arteritic anterior ischemic optic neuropathy. The full study is planned to follow participants for as long as five years. ()
What I could verify about the presentation and reporting
Life Biosciences announced that it would present the results at Eyecelerator during the American Academy of Ophthalmology meeting. The event listing confirms the October 8 Eyecelerator program. As of October 12, the material I could verify that gives detailed human results is the company’s release; I could not locate a publicly accessible patient-level slide deck, visual-field printouts, presentation transcript, or detailed independent conference account. Available news summaries largely repeat the company’s reported numbers rather than adding patient-level data. ()
That distinction matters: the reported threshold is a company-reported observation, not a publicly inspectable result that outside clinicians can reanalyze.
What is—and is not—known about the three participants
The trial registry supplies eligibility limits. It does not provide the first three participants’ individual clinical records. The company has not released a patient-by-patient table.
For the full table, please open this article on visualfieldtest.com.
For the glaucoma cohort, the registry defines eligible visual-field loss as mean deviation from −6 to −20 decibels and an eligible eye-pressure value below 30 millimeters of mercury. These limits should not be mistaken for the actual values of the three treated participants. ()
What does “28% of points improved by more than 4 decibels” mean?
About 15 locations—not 28% of vision restored
The 24-2 visual-field pattern tests points across the central visual field. Depending on whether the blind-spot locations are counted in the denominator, the conventional point count is 52 or 54. Twenty-eight percent of either count is about 15 locations.
This does not mean that 28% of lost vision came back. A visual-field test records sensitivity at discrete locations; the company did not report how large the average improvement was, how much each location had been damaged, or what happened at the remaining locations.
A change greater than 4 decibels at a previously impaired location could be important if it is repeatable. But a list of points crossing a threshold is not the same as an overall improvement in the visual field. Improvements in some locations can coexist with worsening or unchanged sensitivity elsewhere. The registry identifies change in overall mean deviation as a visual-field measure; the announcement instead highlights the percentage of locations crossing the 4-decibel threshold. Neither the maps nor the global scores were released. ()
The crucial unanswered questions
The public disclosure does not show:
whether the improved locations formed a coherent cluster or were scattered;
whether those locations matched previously damaged areas;
whether the same locations improved on a second or third post-treatment test;
whether other locations worsened enough to offset the gains;
changes in mean deviation, visual field index, or pattern standard deviation;
whether the untreated fellow eye changed similarly.
Those details would help distinguish a plausible recovery pattern from a noisy or broadly shifted test result.
How often can a visual-field point improve by more than 4 decibels by chance?
Variability is greatest in damaged regions
A visual-field result is not a perfectly stable reading of nerve function. The pointwise test-retest variability differs by location and by the amount of existing damage. In a study of glaucoma patients tested repeatedly, sensitivity at locations with moderate loss sometimes ranged from a near-normal result to an absolute defect across tests. Other work finds greater variability at lower sensitivities, with a measurement floor affecting very advanced damage. ()
A large study of 4,044 glaucoma eyes found substantial overall test-retest variation, and found that test results at central locations tended to be more correlated across tests than those at peripheral locations. That overall measure is not a point-specific probability that a 4-decibel improvement will happen, but it reinforces why a one-time change needs context. ()
For a rough illustration—not a patient-specific estimate—if a damaged location has a paired test-to-retest difference standard deviation of 3 decibels, a one-sided improvement greater than 4 decibels would occur about 9% of the time under a simple bell-curve model. If that standard deviation is 6 decibels, the estimate is about 25%. At a relatively healthy location, variability is much lower, so a 4-decibel gain is much less likely. Published descriptions of perimetric variability support a wide range, rather than one universal probability for every point. ()
Why 15 points cannot be treated as 15 independent coin flips
Visual-field locations are not independent. A participant’s alertness, fatigue, fixation, test comprehension, and general performance can influence many locations in the same session. Learning can also improve results across a field. Those shared influences make a cluster of improved points more likely than a calculation that assumes every point fluctuates independently.
To show how much the answer depends on assumptions, consider an illustrative correlated-error model for 52 locations. Suppose each location has a 10% chance of improving by more than 4 decibels from measurement variation alone. If locations were independent, the chance of at least 15 improvements would be about 0.04%. With modest positive correlation among locations, a rough overdispersed model puts it in the low single digits, rather than near zero. If the individual-location chance were 20%, the corresponding estimate could range from roughly 8% under independence to about 15–30% under illustrative positive-correlation assumptions.
These are sensitivity calculations, not estimates of what happened to these participants. They assume a simplified common degree of pointwise variability and correlation; actual fields mix normal, moderately damaged, and severely damaged locations. The true chance for any of the three participants cannot be calculated without their baseline and repeat fields, test reliability values, and pointwise error structure. Still, the exercise shows why “15 points” is not automatically extraordinary—and why the raw maps and repeated tests are essential.
Learning, regression to the mean, and test quality
In one study of newly tested glaucoma patients,
Support the show
How Accurate Is Your Eye Pressure Test? A Patient’s Guide to IOP Measurement Methods
2026/10/11
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/how-accurate-is-your-eye-pressure-test-a-patient-s-guide-to-iop-measurement-methods
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
How Accurate Is Your Eye Pressure Test? A Patient’s Guide to IOP Measurement Methods
Was your test a puff of air, a blue light and a small tip touching your eye, or a tiny probe tapping your cornea? Each is a way to estimate intraocular pressure (IOP)—the fluid pressure inside the eye. The tests may give different numbers, even when they are done minutes apart. That does not automatically mean one test was wrong: they use different methods, and each is affected by the eye’s surface, the testing technique, and ordinary changes in pressure over time.
This guide explains how to recognize the main tests, what their readings can and cannot tell you, and when another measurement might help. The short version: Goldmann applanation tonometry is the usual clinical reference, not a perfect reading of “true” pressure. A number is most useful when interpreted alongside your cornea, optic nerve, visual field, and previous readings.
First, what does “accurate” mean?
A tonometer does not usually place a sensor inside the eye. Most estimate pressure by observing how the cornea—the clear front window of the eye—responds to air or gentle contact. The cornea’s thickness, shape, stiffness, hydration, and surface can affect that estimate.
It helps to distinguish two ideas:
Agreement asks whether a method gives a similar number to a reference method.
Repeatability asks whether the method gives similar numbers when the test is repeated.
A device can be repeatable yet consistently read a little high or low. And two devices can have almost the same average result across a group of people while disagreeing by several millimeters of mercury (mmHg) in a particular person.
How to read the scores in this guide
The 1–100 ratings below are editorial comparison scores—not percentages, validated medical scores, or an official ranking. They are broad estimates of how useful a method is for matching established clinical measurements in a trained, untreated adult with a structurally typical cornea. The assessment considers agreement with Goldmann applanation tonometry and, where available, direct pressure measurements; systematic bias; repeatability; and how well the method holds up across pressure levels and patient characteristics.
A score of 90 does not mean “90% correct.” A few points’ difference is not meaningful proof that one device is better for an individual. Evidence-confidence labels describe how confident we are in the comparison, not whether a reading from that device is guaranteed to be right.
When studies report 95% limits of agreement, those limits describe the range in which about 95% of individual paired differences between two methods fell in that study or pooled analysis. They are more informative about person-to-person differences than an average difference alone—but they still do not say which method was closer to the true pressure.
At a glance: how the methods compare
For the full table, please open this article on visualfieldtest.com.
The comparison evidence is not a clean contest between identical devices: studies differ in patient groups, instrument models, pressure ranges, and testing procedures. In a large systematic review, agreement with Goldmann varied substantially among methods; for example, pooled 95% limits of agreement were roughly −4 to +4 mmHg for some non-contact tests, and wider for several other devices. The review also found notable differences between studies and between repeated measurements. Systematic review of tonometer agreement ()
Why Goldmann is the clinical reference—but not a perfect “truth”
Goldmann applanation tonometry: the blue-light test
How it works: A clinician looks through a slit lamp—a microscope used during an eye examination—and uses a small prism to flatten a tiny area of the cornea. The instrument estimates pressure from the force needed to flatten it.
What it feels like: Numbing drops are usually used, along with fluorescein dye, which makes the contact point visible under blue light. The prism briefly touches the cornea. The procedure usually takes only a short time for each eye. You may feel the drops or notice the light, but the eye should not feel sharp pain.
Where it is used: Goldmann is a major reference method in glaucoma care. For example, the United Kingdom’s National Institute for Health and Care Excellence recommends Goldmann-type applanation tonometry in glaucoma assessment and says referral decisions should not be based solely on a non-contact reading. National Institute for Health and Care Excellence glaucoma recommendations ()
Why it is trusted: Clinicians have extensive experience with it, the technique is well established, and many studies and clinical decisions use it as the comparison standard. Keeping to the same method over time can make it especially helpful for tracking change.
Why it is not a direct measurement of true pressure: Goldmann estimates pressure through the cornea. Its original design assumes average corneal properties; differences in thickness and biomechanics can therefore change the reading. It is commonly used as the clinical reference because it is established and practical—not because it directly measures fluid pressure inside the eye. A true direct measurement requires placing a pressure sensor or cannula inside the eye, something generally limited to research or an operation. In a small human cadaver-eye study, Pascal dynamic contour readings were closer to experimentally set intracameral pressure than Goldmann readings; cadaver eyes, however, are not the same as living eyes in routine practice. Intracameral manometry comparison ()
Perkins handheld applanation tonometry
How it works: The Perkins instrument uses the same basic applanation principle as Goldmann but is handheld, rather than mounted on a slit lamp.
What it feels like: It usually requires numbing drops and fluorescein dye, and the instrument briefly touches the cornea. It can be used with a patient sitting or lying down, depending on the situation.
Where it is used: Its portability can be useful in hospitals, for patients who cannot sit at a slit lamp, and when pressure must be checked with someone lying down. It is also used in some children and in people under anesthesia. It has a similar underlying measurement approach to Goldmann, but a handheld test still depends on careful positioning and technique. American Academy of Ophthalmology assessment of rebound tonometry in children ()
Air-puff or non-contact tonometry
How it works: A machine sends a quick puff of air toward the cornea and detects how the cornea responds. There is no instrument touching the eye.
What it feels like: You rest your chin and forehead on the machine and look at a target. The puff can be startling, but it is over quickly. Numbing drops and fluorescein are not needed.
Where it is used: It is often used for routine screening because it is quick and does not require corneal contact. The exact mix of devices in community eye-care settings varies. Reliable country-by-country comparisons of how widely each type of tonometer is used are lacking, so a device’s availability in a country should not be taken as evidence that it dominates there.
How to interpret it: A systematic review found that pooled air-puff results were among the methods that most closely matched Goldmann on average. But studies still showed individual differences of several mmHg, and the result can be affected by the cornea and by device design. Air-puff testing is useful, but a concerning reading may need confirmation with an applanation test or another suitable method. Systematic review of tonometer agreement ()
Rebound tonometry: the tiny-probe test
How it works: A handheld device briefly propels a very light, disposable probe toward the cornea. The device measures how the probe slows and rebounds. A clinic-based iCare session typically takes several readings and combines them.
What it feels like: You may hear a quiet click or feel a light tap. Topical anesthetic drops are usually not needed.
Where it is used: Clinic-based rebound devices can be useful for children, bedside assessments, and people who find a slit lamp difficult. Models differ: a model designed for a trained clinician should not be assumed to work the same way as a model designed for self-testing. American Academy of Ophthalmology reviewers found that children’s readings from rebound tonometry were often 2–3 mmHg higher than Goldmann readings in the small number of comparable studies they reviewed. That does not mean every rebound reading should be reduced by 2–3 mmHg; it means the methods can differ. American Academy of Ophthalmology assessment of rebound tonometry in children ()
iCare HOME and HOME2: home pressure checks
iCare HOME devices use rebound tonometry but are designed for eligible patients to measure their own pressure after instruction. Home measurement is a way to collect more readings at different times—not a reason to treat each individual number as exact.
A systematic review and meta-analysis published in 2026 found little average difference between iCare HOME and Goldmann readings, but the spread between individual paired readings remained substantial: estimated limits were about ±5 mmHg. The review rated the evidence ver
Support the show
Could Rhopressa Protect the Optic Nerve, Not Just Lower Eye Pressure? A New Trial Will Count Individual Glaucoma Nerve Cells
2026/10/10
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/could-rhopressa-protect-the-optic-nerve-not-just-lower-eye-pressure-a-new-trial-will-count-individual-glaucoma-nerve-cells
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Could Rhopressa Protect the Optic Nerve, Not Just Lower Eye Pressure? A New Trial Will Count Individual Glaucoma Nerve Cells
A newly registered study is asking an unusually direct question: does netarsudil (Rhopressa) preserve retinal nerve cells better than timolol when used by people with open-angle glaucoma? Rather than relying only on standard scans that measure the thickness of broad retinal layers, the researchers plan to use adaptive optics optical coherence tomography to image and count cells in the living eye.
It is an exciting idea, but this is a small, early clinical test—not proof that Rhopressa protects the optic nerve independently of pressure. The trial’s design, its short treatment periods, and unresolved questions about the new imaging method all matter. So does a fundamental challenge: two medicines can produce similar pressure readings in the clinic while having different effects on pressure overnight, blood flow, or pressure variability.
The new trial: what is registered
The Phase 4 study, NCT07847073, is titled “Adaptive Optics OCT Evaluation of Rhopressa’s Effects on the Retinal Ganglion Cells in Glaucoma Patients.” It was first posted on September 29, 2026, after submission on September 22. The registry lists it as recruiting, with an estimated start date of October 1, 2026. That estimated date is not confirmation that the first participant was enrolled on that day. The planned study completion date is January 1, 2028. ClinicalTrials.gov study record ()
For the full table, please open this article on visualfieldtest.com.
The two treatment regimens are:
Netarsudil 0.02%: one drop in the study eye once daily in the evening for six months.
Timolol maleate 0.25%: one drop in the study eye twice daily, morning and evening, for six months.
One group receives netarsudil first and then timolol; the other receives timolol first and then netarsudil. Trial interventions and outcomes ()
Who can take part—and what the registry does not say
Participants must be at least 18 years old and have open-angle glaucoma with structural damage to the optic nerve or retinal nerve fiber layer, plus matching visual-field defects. Corrected visual acuity must be 20/50 or better, and participants must be able to fixate for imaging.
The allowed refractive range is a spherical equivalent from +3 to −6 diopters, with cylinder under 3 diopters. People who are new to pressure-lowering drops, or who have completed a medication washout, must have an intraocular pressure between 18 and 34 millimeters of mercury. The record excludes people with certain other retinal diseases or optic-nerve conditions, or who cannot safely undergo washout. It does not state a formal glaucoma severity category, such as mild, moderate, or advanced. Nor does it publish the washout duration or specify different washout periods for different medicines. The record describes a switch at month six but does not specify a separate washout between treatment periods. Eligibility criteria and study arms ()
That missing information matters. A medication-free pressure reading after washout establishes eligibility, but it does not prove that participants will have the same pressure exposure on both study medicines. And an immediate switch at month six, if that is what happens, would be different from a design with a defined washout between periods.
Why a crossover design helps—and why it is awkward here
A crossover can be efficient in a small study because each participant receives both medicines. Each person therefore serves as their own comparison, reducing the influence of differences such as age, starting cell density, and individual disease severity.
But glaucoma nerve-cell loss creates a serious crossover problem: dead nerve cells do not come back when a treatment period ends. A washout may reduce the immediate pressure-lowering effect of a drop, but it cannot wash out accumulated neuronal injury or any lasting biological effect on survival. The second six-month period also always occurs later in time, when a participant’s disease may have progressed further.
Randomizing treatment order helps balance this period effect across the group, but with only 13 participants, the two treatment sequences will be small. Other concerns include:
Carryover: a medicine’s pressure effects may fade after stopping, but a lasting effect on cell health—or a lasting harmful effect—could remain.
Washout risk: stopping glaucoma treatment can raise pressure. The registry says washout is required for some participants but does not state the duration.
Unequal periods: retinal damage may progress at a different rate in different months, or in different retinal locations. A change during the second period may not be fairly compared with a change during the first.
Irreversible measurement: if cells were lost in period one, that loss remains in period two. A later treatment cannot restore the original starting count.
The design is reasonable for an exploratory study, but it is not an easy way to isolate the effects of two treatments on a slow, irreversible disease.
Why counting individual cells is different from a standard glaucoma scan
Routine optical coherence tomography is a central tool in glaucoma care. It commonly measures the retinal nerve fiber layer, which contains ganglion-cell axons, and the thickness of the ganglion cell–inner plexiform layer or the ganglion cell complex. These measurements are valuable, but they are measurements of layers, not counts of living nerve-cell bodies. A layer’s thickness can be affected by several tissue components and does not always tell us whether an individual cell has died.
Adaptive optics optical coherence tomography combines two imaging ideas. Optical coherence tomography produces depth-resolved cross-sectional images of retinal tissue. Adaptive optics measures and corrects distortions caused by the eye’s own optical imperfections, using a deformable mirror to sharpen the image. The result can show structures only a few micrometers across.
Published research systems have reported three-dimensional resolution around 2.4 × 2.4 × 4.7 micrometers. Another research-grade system reported a theoretical lateral resolution of 2.5 micrometers and a nominal depth resolution of 3.7 micrometers. Researchers have used these systems to image the ganglion-cell layer at small macular locations, generally in fields about 1.5 degrees across, at retinal locations ranging from near the fovea to roughly 12–13 degrees away. Foundational adaptive-optics imaging study and research on imaging ganglion-cell somas ()
Can it really identify and track the same cells?
Researchers can often recognize cell-like structures by their size, shape, depth, reflectance, and position relative to other retinal landmarks. They register images from repeated scans—aligning them to the same tissue locations—and average many registered images to reduce speckle and sharpen cell outlines. In one early study, averaging roughly 100–160 registered image volumes improved the visibility of ganglion-cell-layer somas. Imaging and quantifying ganglion cells ()
There is proof of feasibility, but not yet a large, validated clinical method for tracking cell death. In one glaucoma case followed for two years, an adaptive-optics study reported declining soma counts in four small regions of an arcuate defect. The estimated annual losses differed across regions, from 3.1% to 6.2%. This was a conference abstract about one participant, not a large longitudinal validation study. 2023 study abstract ()
There is also an important distinction between seeing a soma in the ganglion-cell layer and proving that it is a retinal ganglion cell. Current images identify cells by anatomy and appearance, not by a molecular label. The ganglion-cell layer contains a small number of other cell types, including displaced amacrine cells, and the living image may not always reveal a cell’s identity with certainty. Researchers have also imaged glial cells and macrophage-like cells elsewhere in the retina. The imaging method is promising, but “individual ganglion-cell counts” should not be understood as molecularly confirmed identification of every cell. Research review of adaptive-optics imaging and study of presumed displaced ganglion cells ()
Eye motion is another challenge. Even small eye movements can misalign images at cellular scale. Image registration helps correct motion, but it is a necessary processing step, not a guarantee that repeated visits sample precisely the same cells. Scan quality, fixation, optical clarity, and the ability to reproduce retinal locations all affect the count.
A related repeatability study gives a useful warning. When researchers recounted bright, large, presumed displaced ganglion cells at seven locations in one healthy participant six months apart, the reported 95% limits of agreement were about ±24.8%. That result is not a direct estimate of how this glaucoma trial’s primary outcome will perform: it involved a small sample and a different cell population. But it shows why a cell-resolved image is not automatically a low-noise measurement. A robust, widely replicated estimate
Support the show
wake up glaucoma professionals, people hate doing the visual field test ever not even once a year! we hate, everyone that I talk to hates it. We are s...